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2. Summary 
Lung cancer with its most prevalent form non-small-cell lung carcinoma (NSCLC) is one 
of the leading causes of cancer-related deaths worldwide and is characterized by early 
metastatic spread. TGF-β is one of the growth factors that can be involved in the 
regulation of this process. Lung cancer is generally treated with chemotherapeutic 
drugs, e.g. with cisplatin, often in combination with different inhibitors, such as MEK 
inhibitors (MEKi). An important obstacle for lung cancer patients is the chemotherapy-
induced anemia that can be treated with erythropoietin (Epo). Unfortunately, Epo was 
found to have tumor-stimulating effects. 
To establish reliable and reproducible experimental conditions, standard operating 
procedures for the NSCLC cell lines H1975 and H838 were developed. Cisplatin was 
shown to induce apoptosis in a dose-dependent manner in H838 cells. The MEKi 
U0126 was found to rescue H838 cells of cisplatin-induced apoptosis by arresting the 
cells in the cell cycle phase G1 and this effect could be reproduced with clinically 
relevant MEK inhibitors. Epo treatment of the cell line H838 resulted in decreased 
cisplatin sensitivity. To identify the differences in Epo-induced signaling in erythroid 
progenitor cells and the cell line H838, a dynamic pathway model was established that 
was able to describe the Epo-induced dynamics of the activation of the JAK2/STAT5 
pathway in both cell types. The mathematical model predicted 8 cell type-specific 
parameters. Among these, the SOCS3 mRNA turnover rate was predicted to be slower 
in CFU-Es which was experimentally validated by qRT-PCR. Moreover, it was shown by 
genome wide expression profiling, that TGF-β treatment of NSCLC cells led to the 
upregulation of EMT genes and the downregulation of cell cycle genes. The TGF-β 
pseudoreceptor BAMBI was found to be downregulated in NSCLC. Its reconstitution 
resulted in a decreased TGF-β signaling in the cell line H1975. 
In conclusion, the study shows that MEKi treatment in combination with cisplatin-based 
chemotherapy poses a potential risk for lung cancer patients. Furthermore, the 
presence of EpoR in NSCLC cell lines results in response to Epo stimulation in a 
decreased sensitivity to cisplatin. Finally, TGF-β was verified to induce EMT in NSCLC 
and BAMBI was identified as a potential tumor suppressor in lung cancer. These studies 
show that molecular alterations can define responsiveness to therapeutic agents. 
Zusammenfassung  6 
 
  
3. Zusammenfassung 
Lungenkrebs mit seiner am weitesten verbreitete Form des nicht-kleinzelligen 
Lungenkarzinoms (NSCLC) ist weltweit eine der häufigsten Ursachen für 
Krebstodesfälle und ist durch eine frühe Metastasierung charakterisiert. Diese kann 
durch TGF-β reguliert sein. NSCLC wird im Allgemeinen mit dem Chemotherapeutikum 
Cisplatin behandelt, oft auch in Kombination mit einem MEK Signalweginhibitor (MEKi). 
Ein großes Problem für Lungenkrebspatienten ist die Chemotherapie induzierte 
Anämie, die aber mit Erythropoietin (Epo) behandelt werden kann. Leider wurde 
festgestellt, dass Epo auch eine stimulierende Wirkung auf den Tumor haben kann. 
Um zuverlässige und reproduzierbare Bedingungen zu ermöglichen, wurden 
Standardvorgehensweisen für die NSCLC Zelllinien H1975 und H838 etabliert. Es 
wurde gezeigt, dass Cisplatin Apoptose in H838 Zellen induziert. Bei der zusätzlichen 
Gabe von MEKi U0126 oder anderen klinisch relevanten MEKi wurde festgestellt, dass 
H838 Zellen durch einen Arrest in der Zellzyklusphase G1 vor der Apoptose gerettet 
werden können. Auch die Gabe von Epo konnte der Apoptose entgegen wirken. Um 
Unterschiede in der Epo induzierten Aktivierung des JAK2/STAT5 Signalweges von 
erythroiden Vorläuferzellen und H838 Zellen zu identifizieren, wurde ein 
mathematisches Modell etabliert. Von den 8 vorhergesagten zelltypspezifischen 
Parametern, wurde die SOCS3 mRNA Degradationsrate durch qRT-PCR experimentell 
validiert. Darüber hinaus wurde durch genomweite Expressionsanalyse gezeigt, dass 
TGF-β zur Hochregulierung von EMT Genen und der Herunterregulierung von 
Zellzyklusgenen in H1975 Zellen führte. Außerdem konnte gezeigt werden, dass der 
TGF-β Pseudorezeptor BAMBI in NSCLC herunter reguliert war und eine Rekonstitution 
in H1975 Zellen zu verminderter TGF-β Signalwegakivierung führte. 
Zusammenfassend wurde die Behandlung mit MEKi parallel zu Cisplatin als 
potenzielles Risiko für Lungenkrebspatienten identifiziert. Ferner wurde gezeigt, dass 
die EpoR Expression in NSCLC Zelllinien bei Epo Gabe zu einer verringerten 
Sensitivität gegenüber Cisplatin führt. Darüber hinaus wurde TGF-β als ein EMT 
induzierender Faktor in NSCLC bestätigt und BAMBI als ein potenzieller 
Tumorsuppressor in Lungenkrebs identifiziert. Diese Studien zeigen, dass molekulare 
Veränderungen die Wirkung von Therapeutika bestimmen können. 
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4. Introduction 
4.1 Lung cancer 
Lung carcinoma is one of the leading causes of cancer-related deaths worldwide. The 
main types of lung cancer are small-cell lung carcinoma (SCLC) and non-small-cell lung 
carcinoma (NSCLC). The most frequent form with around 85% is NSCLC and can be 
classified into squamous-cell carcinoma, large-cell carcinoma and with 40% the most 
prevalent subgroup adenocarcinoma [1]. The origin of NSCLC is believed to be lung 
alveolar epithelial cells type II (AECII) [2-5]. 
 
4.1.1 Genetic alterations in lung cancer 
Lung cancer is known for a high metastasis rate independent of tumor size. This key 
medical problem is often combined with a high mutation rate in the genome, especially 
for genes that are involved in processes like cell growth, proliferation and migration 
indicating a direct correlation. Most prevalent mutations in oncogenes were observed for 
EGFR (epidermal growth factor receptor), KRAS, ALK (anaplastic lymphoma kinase), 
BRAF, MET, TP53 (p53), PIK3CA and ERBB2, MAP2K1 and NRAS [6, 7] (Figure 1). 
Therefore, specific targeted therapies by small molecule inhibitors or therapeutic 
antibodies based on the mutation profile of the tumor are applied for selected cases.  
 
Figure 1: Significantly mutated genes in lung adenocarcinomas. The bars indicate the number of 
somatic mutations in each indicated gene in 188 tumor and normal tissue pairs analyzed by PCR-based 
methods [7]. 
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4.1.2 Dysregulated cell cycle in lung cancer 
The formation of lung tumors is often induced by uncontrolled proliferation that might 
have its origin in a dysregulated cell cycle. The cell cycle starts with the interphase that 
consists of G1 (gap1), S (synthesis) and G2 (gap2) phase in which the cell grows, 
duplicates the DNA and prepares for the cell division in the M (mitotic) phase, in which 
the cell splits into two daughter cells. The cell can rest in the G0 (quiescent) phase or 
directly start a new cycle with G1 phase. The two main regulatory classes of the cell 
cycle phases are cyclins and cyclin-dependent kinases (CDKs). They are conserved 
among all eukaryotes and form an active heterodimer where different cyclin-CDK 
combinations determine the target proteins that are phosphorylated. Arrest of the cell 
cycle can be achieved by expression of p21 (CDKN1A, cyclin-dependent kinase 
inhibitor 1) or p27 (CDKN1B) that regulate G1/S cell cycle transition by inhibiting cyclin-
CDK complexes and is controlled either in a p53-dependent or –independent manner 
[8-10]. One possibility how the cell can react to extracellular or intracellular influences to 
either initiate cell cycle arrest or progression is via the MAPK (mitogen-activated protein 
kinase) pathway. Activation of the MAP kinase ERK (extracellular signal-regulated 
kinase) is also required to enter the S phase [11-13] and inhibition of ERK results in cell 
cycle arrest [14]. As many components that are involved in the regulation of the cell 
cycle, e.g. p53 or MAPK pathway components, are often mutated in lung cancer cells, 
uncontrolled cell division is an issue that needs to be understood in more detail to 
enable the development of strategies for effective medical treatments. 
  
4.2 MEK inhibitor treatments in lung cancer 
To overcome uncontrolled cell proliferation caused by mutations that increase or 
constantly activate MAP kinase signaling, MAPK inhibitors are currently tested in clinical 
trials. The RAS–RAF–MEK1/2–ERK1/2 pathway is the best characterized MAPK 
pathway and one of the most frequently dysregulated signaling cascades [15]. KRAS, 
for instance, is with 17% one of the most frequent mutated genes in lung cancer [16]. 
The mitogen-activated protein kinase kinase MEK is synthesized in the two isoforms 
MEK1 and MEK2 that share a high homology and are thus an applicable drug target 
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[15]. MEK inhibitors (MEKi) are small molecules that inhibit one or both isoforms and 
can be subdivided into ATP non-competitive and ATP competitive inhibitors. Most of the 
inhibitors do not directly compete but rather bind to an allosteric site adjacent to the ATP 
binding site and thus preventing ATP binding [17]. Available MEK inhibitors are U0126, 
Cl-1040 (PD184352), and in currently running clinical trials AZD8330 (ARRY-424704), 
refametinib (BAY 86-9766, RDEA119), cobimetinib (GDC-0973, XL-518, RG7421), 
E6201, MEK162 (ARRY-438162), pimasertib (AS703026, MSC1936369B), RO4987655 
(CH4987655), RO5126766 (CH5126766), TAK-733, GDC-0623, WX-554, selumetinib 
(AZD6244, ARRY-142,886), PD0325901 and trametinib (GSK1120212) with the last 
three tested for NSCLC (Table 1).  
 
Table 1: MEK inhibitors in clinical trials, adapted from Zhao et al. [15]; Abbreviations: HCC: 
hepatocellular carcinoma; CRC: colorectal cancer; NSCLC: non-small-cell lung carcinoma; 
EK1/2 inhibitors Company Current stage of clinical development 
AZD8330 (ARRY-424704) AstraZeneca, UK and Array Biopharma, USA Phase I 
Refametinib (BAY 86-9766, 
RDEA119) 
Bayer, Germany and Ardea 
Bioscience, USA Phase II (in HCC) 
Cobimetinib (GDC-0973, 
XL-518, RG7421) 
Exelixis, USA and Hoffmann-La 
Roche, Switzerland Phase III (in melanoma) 
E6201 Eisai, USA Phase I 
MEK162 (ARRY-438162) Array Biopharma, USA and Norvartis, Switzerland 
Phase III (in melanoma, low-
grade serous ovarian, fallopian 
tube, or peritoneal cancer) 
PD0325901 Pfizer, USA Phase II (in NSCLC, CRC, and pancreatic cancer) 
Pimasertib (AS703026, 
MSC1936369B) EMD Serono, USA 
Phase II (in melanoma, CRC, 
pancreatic cancer, and ovarian 
cancer) 
RO4987655 (CH4987655) Hoffmann-La Roche, Switzerland Phase I 
RO5126766 (CH5126766) Hoffmann-La Roche, Switzerland Phase I 
Selumetinib (AZD6244, 
ARRY-142,886) 
AstraZeneca, UK and Array 
Biopharma, USA Phase III (in NSCLC) 
TAK-733 Takeda, Japan Phase I 
Trametinib (GSK1120212) GlaxoSmithKline, UK Phase III (in melanoma) 
GDC-0623 Genentech, USA Phase I 
WX-554 Wilex, Germany Phase I/II 
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Trametinib was the first MEK inhibitor and is so far the only one that was approved for 
the treatment of patients with BRAF V600E/K-mutant melanoma by the U.S. Food and 
Drug Administration (FDA) in 2013 [18]. For the treatment of lung cancer, promising 
results could be observed with selumetinib in combination with docetaxel as it prolonged 
progression-free survival and increased response rates in patients with KRAS-mutated 
NSCLC in a randomized phase II trial [19]. Despite these achievements, also toxic 
effects were caused by some MEK inhibitors leading to termination, e.g. of a phase II 
study in NSCLC patients with PD0325901 due to ocular and neurological toxicity 
(ClinicalTrials.gov Identifier: NCT00174369) [20]. This development points out the 
importance and need of a better understanding of how MEK inhibition works in detail.  
 
4.3 Chemotherapeutic treatments in lung cancer 
Depending on the stage of the tumor and the patient’s state of health, NSCLC can be 
treated with surgery, radiotherapy and/or chemotherapy. Due to the fact that lung 
cancer metastasizes already at early stages, widely spread metastases can often be 
found already at the time of the first diagnose [21]. As standard of care, lung cancer 
patients are treated with platinum-based chemotherapeutic drugs [22], such as cisplatin 
or cis-diamminedichloroplatinum(II). It was the first FDA-approved platinum compound 
for cancer treatment in 1978 and although several analogues were synthesized and 13 
even tested in clinical trials, just carboplatin and oxaliplatin have additionally been FDA-
approved so far [23, 24] (Figure 2). 
 
 
Figure 2: Platinum-based FDA-approved drugs used for chemotherapy (taken from Yonezawa et al. [25]).  
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Cisplatin is given to the patient as an intravenous infusion with a dose of 80 mg/m2 at 
day 1 of a therapy cycle. This is repeated every three weeks for 4 cycles [26]. With an 
average body surface area of 1.73 m2 [27], around 140 mg cisplatin is given per one 
treatment. As the human body contains between 5 and 6 liters blood, the concentration 
in the human body is approximately 20-30 mg/l cisplatin or less if degradation 
processes are taken into account. Clearance of platinum compounds is triphasic in 
nature, with a distribution half-life of 13 minutes, elimination half-life of 43 minutes, and 
terminal half-life of 5.4 days for total cisplatin [28, 29]. 
 
4.3.1 Cisplatin-induced apoptosis 
Cisplatin-induced apoptosis is well described in literature (Figure 3). The drug is a small 
molecule that can enter the cell by diffusion, but also some transporters are suggested 
to play a role like CTR1 (copper transporter 1) [30]. After reaching the nucleus, cisplatin 
binds to purine bases of the DNA and thus cross-links the DNA strands (inter- and intra-
strand cross-links). This leads to the initiation of the repair mechanisms NER (nuclear 
excision repair) and MMR (mismatch repair) that are linked to cell cycle arrest [30].  
The key player of these repair mechanisms but also of cisplatin-induced apoptosis that 
takes place if the DNA damage failed to be repaired is p53. This p53-involved process 
is rather complex and includes many signaling components which allow the cell to fine 
tune the process. If the damage is irreparable, p53 levels are strongly increasing and 
the cells start to undergo the apoptotic program. This includes activation of the AKT and 
MAPK (JNK, p38 and ERK) pathways [31-44]. These pathways are connected to 
several Bcl-2-family members (anti-apoptotic: Bcl-2, Bcl-xL; pro-apoptotic: Bad, Bax, 
Bak, Bcl-xS, Bik, Bim, Bid) that among others regulate the cytochrom c release from the 
mitochondria that takes place, e.g. in renal tubule cells after about 9 hours upon 
treatment [45]. In the next step the apoptosome is formed which results in the final part 
of apoptosis, the cleavage of caspases (caspase-9, caspase-3 and caspase-8) [45, 46]. 
Besides anti-apoptotic Bcl2-family members, some other players can also negatively 
regulate p53-induced apoptosis, including IAPs (Inhibitor of apoptosis proteins, e.g. 
XIAP) [35, 47, 48] and Mcl1 that are mainly activated by the AKT pathway. Mdm2 that 
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inhibits p53 is expressed as a negative feedback loop by the binding of p53 to the DNA 
[30]. Moreover, p53 also induces its own expression besides other target genes like 
PUMA, CDKN1A (p21), Bcl-xL, BAX, CCND1 (cyclin-D1), CCNG (cyclin-G), GADD45 
and NOXA [37, 49, 50], that are responsible for regulation of cell cycle and apoptosis. 
For instance, GADD45 regulates the cell cycle arrest at G2 phase and is involved in 
DNA repair mechanisms [51, 52]. 
 
 
 
Figure 3: Cisplatin-induced apoptosis. Cisplatin intercalates in DNA and thus activates p53. The start 
of DNA repair mechanisms is coupled to cell cycle arrest. Increasing amounts of p53 lead to the induction 
of the apoptotic program with the key pathways MAPK and AKT that regulate the Bcl-2 members which 
are amongst others key players for the cleavage of caspases. 
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4.3.2 Resistance to chemotherapeutic treatments 
A complication that many lung cancer patients are suffering from is the resistance to 
chemotherapeutic drugs like cisplatin. Even if the treatment is quite effective at the 
beginning, many cancer patients relapse with a cisplatin-resistant disease [23, 53]. 
Although the exact mechanism is not known, some possibilities are suggested in the 
literature. Resistance to cisplatin that is based on genetic alterations can be found for 
instance in human lung and cervical cancer cell lines that over-express HSP27, IAPs or 
AKT, or have constitutive activated AKT levels [54, 55]. AKT seems to play a key role in 
resistance mechanism as it was shown that inhibition of PI3K or knock out of AKT with 
siRNA leads to an increased apoptosis rate upon cisplatin treatment [33, 34]. AKT is 
further suggested to be an upstream key factor in resistance via its targets XIAP, BAD 
and HSP27 [32-35, 48, 54, 56, 57]. Moreover, the microRNA miR-214 was shown to 
target PTEN and thus inducing resistance to cisplatin [58]. Another protein that can be 
involved in the mechanisms of resistance and is highly mutated in 55% of NSCLC 
tumors [59] is the key mediator of apoptosis p53 that also regulates DNA repair and cell 
cycle. Additionally, TP53 is connected to severely reduced tumor suppression and poor 
prognosis in lung cancer [7, 60]. Re-expression of hematopoietic receptors like EpoR is 
discussed in the literature and activation of its downstream components STAT5 and 
Mcl1 result in cell survival in the erythroid system and lymphoblastic leukemia [61, 62]. 
Although cisplatin can be used in combination with other drugs, e.g. paclitaxel [24, 63] 
or MEK inhibitors (Clinical Trial Identifiers: NCT01192165 and NCT02151084, [20]), 
resistance mechanisms are still not fully understood in lung cancer and thus need to be 
further investigated.  
 
4.4 EpoR signaling in lung cancer 
4.4.1 EpoR signaling in the erythroid system 
Chemotherapy-induced anemia can be treated by blood transfusion or by the 
erythropoiesis stimulating agents (ESAs), such as erythropoietin α (Epo-α, Amgen) or 
Epo-β (Roche) which have comparable properties. The Epo receptor (EpoR) and its 
signaling pathway are well characterized in erythroid progenitor cells (CFU-Es, colony 
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forming unit-erythroid) (Figure 4) as it is the key regulator of red blood cell production 
that ensures growth, differentiation and survival of erythroid progenitors in the fetal liver, 
bone marrow and spleen. The biosynthesis of Epo in the kidney is stimulated by 
reduced blood oxygen level [64]. EpoR is a member of the cytokine receptor 
superfamily and is present on the cell surface as a homodimer, which self-interacts at its 
transmembrane domain [65]. After Epo binding, the erythropoietin receptor undergoes a 
conformational change that leads to the phosphorylation of the pre-bound, cytoplasmic, 
tyrosine kinase Janus kinase 2 (JAK2) [66]. The activated JAK2 auto-phosphorylates 
tyrosine residues on the EpoR cytoplasmic domain that serve as docking sites for 
interaction with proteins containing a SH2 domain. EpoR phosphorylation activates the 
phosphoinositide 3-kinase (PI3K) pathway and the MAP kinase cascade of the 
extracellular signal-regulated kinase (ERK1/2) [67]. The latent transcription factor 
STAT5 (Signal Transducers and Activators of Transcription) binds to two tyrosine 
residues of EpoR, is phosphorylated by JAK2 and translocates as a dimer to the 
nucleus where it starts the expression of target genes like CISH (CIS protein, Cytokine-
inducible SH2-containing protein) and SOCS3 (suppressor of cytokine signaling 3), 
which are translated and serve as negative regulators of JAK2/STAT5 signaling back in 
the cytoplasm [68]. CIS inhibits STAT5 activation by binding to EpoR, whereas SOCS3 
directly binds to the kinase domain of JAK2 and EpoR, thereby inhibiting tyrosine-kinase 
activity [62, 69-71]. There are three major classes of proteins involved in the negative 
regulation of EpoR signaling: the protein tyrosine phosphatases SHPs (SH2 domain-
containing protein-tyrosine phosphatase), the protein inhibitors of activated STATs 
(PIAS) and the suppressor of cytokine signaling (SOCS) proteins [71].  
Furthermore, the JAK/STAT pathway is able to activate the MAP kinase p38 leading to 
the stabilization of SOCS3 mRNA [72-74]. On the contrary, miR-203 can negatively 
regulate the SOCS3 mRNA level [75, 76]. Additionally, it has been suggested that Epo 
binding promotes degradation and endocytosis of the Epo receptor [77, 78] and Epo [79] 
(Figure 4). Moreover, EpoR is expressed in several non-hematopoietic tissues including 
myocytes, cortical neurons, and prostatic, breast and ovarian epithelia [80-82]. Besides 
controlling erythropoiesis, Epo is therefore known to have other biological functions 
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such as involvement in the wound healing process [83], rescue of cells from apoptosis 
[84-87] and it plays an important role in the brain's response to neuronal injury [82, 88]. 
 
 
Figure 4: EpoR signaling. Binding of the ligand erythropoietin (Epo) to its receptor EpoR leads to the 
activation of JAK2 that phosphorylates EpoR and thus activates the three main signaling pathways: 
JAK2/STAT5, PI3K/AKT and MAPK. Phosphorylated STAT5 dimerizes, translocates into the nucleus and 
starts the expression of the negative feedback components CISH and SOCS3.  
 
4.4.2 EpoR signaling and its role in tumorigenesis 
Erythropoietin treatment is the standard of care for patients suffering from a 
chemotherapy-induced anemia. Unfortunately, recent studies have shown that Epo can 
have tumor stimulating effects [89] and Epo and EpoR co-expression is shown to be 
associated with poor survival of non-small cell lung cancer patients, even at stage I [90]. 
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The Epo receptor was shown to be present in some cancer cell lines. Protein levels of 
the phosphorylated and unphosphorylated EpoR signaling compounds ERK, AKT and 
STAT5 could be detected in the NSCLC cell line H838 [91]. In H838 cells the SOCS3 
promoter is suggested to be hyper-methylated resulting in reduced expression of 
SOCS3, which leads to constitutively phosphorylated STAT5 and JAK2 [92]. Moreover, 
other NSCLC cell lines, like A549, H661 and H1650, also express EpoR [93-95]. For 
this reason, the treatment of patients with Epo is discussed controversially [91, 96-98]. 
 
4.5 TGF-β signaling in lung cancer 
4.5.1 TGF-β signaling 
Epithelial-to-mesenchymal transition (EMT) plays a crucial role in the tumor progression 
by increasing the invasive capacity of cells. Transforming growth factor beta (TGF-β) is 
a key regulator of EMT. TGF-β signaling (Figure 5) is mediated by the TGF-β 
serine/threonine kinase receptors type I and type II (TGFBR1/2). By binding of the 
ligand, a complex of two receptor homo-dimers is formed, activated and stabilized. This 
active tetrameric receptor complex phosphorylates receptor-regulated SMAD proteins 
(R-SMADs, e.g. SMAD2, SMAD3), which then bind co-SMADs (e.g. SMAD4). The 
SMAD complexes are transported into the nucleus and act as transcription factors for 
multiple target genes [99-102]. Besides the most prominent downstream signaling 
cascade of SMADs, also other pathways can be activated. For instance, the MAP 
kinase pathway is activated via RAS which leads to the phosphorylation of MEK, ERK1 
and ERK2 [103]. Moreover, the ubiquitin ligase TRAF6 binds to TGFBR1 and activates 
Jun/p38 via MAPKKK TAK1 [104, 105]. Additionally, the MAPK pathway is able to target 
R-SMADs including SMAD2 and SMAD3 [106, 107]. Another protein that can be 
activated upon TGF-β stimulation is PI3K which leads to phosphorylation of AKT at Ser-
473 [108, 109]. By inducing the expression of p21, TGF-β also plays a role in regulation 
of cell cycle [110].  
Two TGF-β target genes are SMAD6 and SMAD7 that are classified as inhibitory 
SMADs (I-SMADs). SMAD7 negatively feeds back to the SMAD complexes and 
TGFBR1 [111], whereas SMAD6 negatively regulates SMAD4. The E3 ubiquitin ligase 
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SMURF1 (SMAD ubiquitination regulatory factor-1) ubiquitinates and thus induces 
proteosomal degradation of SMAD1 and SMAD5 and SMURF2 targets SMAD1, 
SMAD2, SMAD3, SMAD6 and SMAD7. Other co-repressors such as SKI, SnoN and 
TGIF attenuate SMAD-mediated transactivation [112]. 
Moreover, BAMBI (BMP and activin membrane-bound inhibitor homolog), a TGF-β 
pseudoreceptor lacking an intracellular serine/threonine kinase domain required for 
signaling, also negatively regulates TGF-β signaling [113] and if over-expressed is able 
to increase proliferation and migration rate in vitro in ovarian cancer [114]. BAMBI was 
found to be epigenetically silenced in bladder cancer [115] and is absent in breast 
cancer [116]. 
 
 
Figure 5: TGF-β signaling: Binding of TGF-β to the receptor hetero-tetramer complex consisting of 
TGFBR1 and TGFBR2 activates the SMAD, AKT and MAPK signaling pathways. The negative regulators 
of the TGF-β signaling pathway are SMURF1 and SMURF2, SnoN and SMAD7 and the pseudoreceptor 
BAMBI. 
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4.5.2 TGF-β and its role in metastasis by inducing EMT 
TGF-β is known to play a dual role in tumor progression by inhibiting tumor growth at 
early stages but promoting tumor invasiveness and metastasis at later stages of tumor 
progression for instance by inducing epithelial-to-mesenchymal transition (EMT) [117-
122]. EMT is characterized by the development of a fibroblastoid phenotype and the 
loss of cell-cell-adhesions by suppression of components that built up junctional 
complexes like E-cadherin [123]. Changes in microfilaments, microtubules and 
intermediate filaments (e.g. Vimentin) further promote the architectural re-organization 
and cell motility [121]. In parallel, production of matrix proteins, e.g. fibronectin and 
collagen is induced. A basic feature of EMT is the nuclear reprogramming which 
involves transcription factors like Snail and Slug, ZEB1 and ZEB2 [121, 124]. Thus, 
EMT is suggested to be the main source for invasiveness and metastasis of tumors. 
Moreover, genetic alterations like mutations or over-expressed/reduced expression of 
molecules that are involved in the TGF-β pathway can induce tumorigenesis. For 
instance, it was shown that high TGF-β levels correlate with poor prognosis in lung 
cancer [125-127]. The most commonly mutated TGF-β pathway genes in human cancer 
are TGFBR2, TGFBR1, SMAD4 and SMAD2 [128]. It was shown in lung cancer that 
TGFBR2 is frequently down regulated, which is connected to high invasion rates and 
poor outcome [129]. Furthermore, a regulatory cascade involving microRNAs and EMT 
regulators is likely to contribute significantly to cancer progression. For instance, the 
miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 
are shown to regulate EMT via e.g. ZEB1, ZEB2, CDH1 (E-cadherin) and VIM 
(Vimentin) in several cancer types [130-134]. Moreover, tumor cells that undergo EMT 
are more resistant to chemotherapy and radiotherapy [135-137]. All these findings 
demonstrate the importance of TGF-β pathway signaling in tumorigenesis, migration 
and invasion, yet the exact mechanisms are still undefined and need to be further 
investigated. 
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4.6 Systems Biology approach 
Every single cell contains a large number of different compounds. Just listing the 
components does not give any information about the dynamics or explain phenotypic 
changes. The complexity of a study of a cellular system increases by taking cellular 
processes, such as signal transduction and regulation processes like DNA methylation, 
transcription, translation, (de)phosphorylation, or proteolytic degradation, into account. 
Cancer cells with genetic alterations even complicate the situation in this study. To gain 
deeper insights into the complexity of signaling and phenotypic changes of lung cancer 
cells upon different stimuli, such as MEK inhibitors, cisplatin, Epo or TGF-β, a systems 
biology approach will be applied. 
Systems biology aims to understand how cellular systems work and how cellular 
processes are regulated. Therefore it comprises quantitative information from 
experiments and computational modeling techniques. It integrates approaches from 
different fields such as biology, chemistry, physics, medicine, mathematics and 
computer science showing its interdisciplinary character [138-140]. Kitano defines 
systems biology as a hypothesis-driven concept (Figure 6A) [141, 142]. Data or 
knowledge is used to establish a computational modeling structure that represents 
assumptions and hypotheses about a biological system. This hypothesis is tested in 
silico by “dry” experiments such as model simulations. If the model passes the test, it is 
experimentally validated in the next step (“wet” experiments) and the model is calibrated 
based on the experimental data. Inadequate models are eliminated and adequate 
models are refined by using the newly acquired quantitative data. 
Mathematical models are an abstract representation of objects and processes. Within 
the available types of mathematical modeling approaches, models based upon ordinary 
differential equations (ODEs) are able to describe the biochemical rate laws. Networks 
of differential equations can model the temporal and spatial dynamics of biochemical 
processes to achieve a better understanding of chemical mechanism or network 
dynamics under various conditions [143]. 
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There are two major approaches in systems biology or systems medicine: bottom up 
and top down (Figure 6B) [144-147]: 
Top-down approach:  
The top-down approach follows a stepwise working plan. The general idea is to start 
with the big picture followed by the breaking down into smaller segments or sub-
systems. Therefore, the starting point is generally a huge data set generated with “-
omics”-techniques such as genomics or transcriptomics. Based on this data, a 
mechanisms, correlation or hidden pattern is tried to be identified or extracted and a 
hypothesis or model is established. Based on the experimental validation, the 
hypothesis can either be rejected or supported. 
Bottom-up approach:  
The bottom-up approach pieces together sub-systems to gain more insights into the big 
picture of complex systems. For that purpose, prior knowledge about a sub-system is 
used for a model which is able to predict the behavior of a system. Specific experiments 
are designed to either validate or refine the hypothesis. At an advanced stage, sub-
systems are placed together and information, e.g. about different pathways, are 
connected to a big and complex model. 
 
A.          B. 
            
Figure 6: Systems Biology (A) works as a hypothesis-driven cycle in which includes quantitative 
experimental data generation, mathematical modeling, in silico predictions, experimental validation and 
design of new experiments (adapted from [140]). (B) Systems biology can follow either a top-down or a 
bottom-up approach. 
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Both approaches are used for biological but also medical and synthetic biology 
purposes. One criticism of the bottom-up approach in this context is hereby that 
physiological changes are predicted purely from molecular events in a cell and thus 
might not be able to fully describe complex phenotypes such as diseases. In contrast, 
the top-down approach starts at the phenotypic level of a specific disease and breaks 
down to functional pathways to identify what is important in a specific disorder because 
it is potentially complete [145, 146]. In general, it is hoped that systems biology and 
systems medicine will reduce the size and the costs of clinical trials and ensure that 
clinicians prescribe the right medicines for the right patient at the right time. The 
improved level of understanding will furthermore result in improved effectiveness in 
pharmaceutical drug development, molecular diagnostics and personalized medicine 
[141, 142]. 
In this work, the integration of large data sets generated by mass spectrometry, 
quantitative immunoblotting, microarray, quantitative RT-PCR, next generation 
sequencing, whole genome sequencing and life cell microscopy will be performed by 
the theoretical cooperation partners in the groups of Prof. Jens Timmer (Freiburg 
University), Prof. Fabian Theis (Helmholtz Zentrum München), Dr. Hauke Busch and Dr. 
Melanie Börries (Freiburg University) and Prof. Thomas Höfer (DKFZ Heidelberg) and 
transferred into mathematical models. 
 
4.7 Objectives 
Lung carcinoma with its most prevalent form non-small-cell lung carcinoma (NSCLC) is 
worldwide one of the leading causes of cancer-related deaths. Due to the fact that lung 
cancer metastasizes already at early stages, most of the patients receive 
chemotherapy, e.g. cisplatin. Even if the treatment is quite effective at the beginning, 
many cancer patients relapse with a cisplatin-resistant disease. Efforts are currently 
undertaken utilizing co-treatments with specific inhibitors for components of signaling 
pathways potentially involved in tumorigenesis.  Although cisplatin-induced apoptosis is 
well-understood, the specific mechanisms contributing to therapy resistance or side 
effects of combined treatments with targeted therapies, e.g. MEK inhibitors, remain 
unresolved. Moreover, cisplatin treatment frequently results in chemotherapy-induced 
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anemia which can be treated with erythropoietin (Epo). However, recent studies showed 
that Epo may have a tumor stimulating effect and therefore the treatment with Epo is 
controversially discussed. 
The aim of this work was to gain insights into signaling pathways that might play a role 
in tumorigenesis or resistance to cisplatin, Epo- and TGF-β-induced signaling pathways. 
The specific aims of this work are: 
 
1. To elucidate whether there is a combinatorial effect of pathway inhibitors, e.g. 
MEK inhibitors, and the chemotherapeutic agent cisplatin in NSCLC cell lines.  
2. To analyze the effect of the presence of a functional EpoR in NSCLC cell lines and 
its impact on cisplatin-based chemotherapy.  
3. To identify the differences in Epo-induced signaling in erythroid progenitor cells 
and the NSCLC cell line H838 by dynamic pathway modeling to better define the 
risk of EpoR expression in lung cancer. 
4. To determine the impact of TGF-β treatment in NSCLC cell lines. 
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5. Results 
5.1 Establishment of Standard Operating Procedures (SOPs) 
To be able to answer the specific aims of this study, such as to elucidate the effect of 
different treatments alone or in combination with other treatments, standard operating 
procedures (SOPs) for the cell cultivation and experiments were defined and 
standardized quantitative assays were established. This includes the agreement on 
conform culture dishes, protocols for thawing cells from glycerol stocks, subculturing 
and amplifying cells. 
 
5.1.1 Identification of cell lines as model system for NSCLC 
As patient material is very limited and processes in tumorigenesis are rather complex, 
the two non-small-cell lung carcinoma (NSCLC) cell lines H838 and H1975 with 
frequent mutations were selected based on literature information (Table 2) as 
experimental model systems to enable specific analysis of single treatments. H838 is 
known to contain significant amounts of the wild type Epo receptor (EpoR), wild type but 
amplified KRAS  [148], a mutated TP53 [149] and a mutated CDKN2A [150]. Moreover, 
the SOCS3 promoter was reported to be hyper-methylated [92]. In contrast, the NSCLC 
cell line H1975 has low levels of EpoR, mutated TP53 and an activating mutation in 
EGFR and PIK3C [150]. The T790M-EGFR mutation found in H1975 cells is known to 
induce resistance to EGFR TKIs (tyrosine kinase inhibitors, e.g. erlotinib, gefitinib) [151]. 
Literature data about MET amplification in H1975 is controversial [151, 152].   
To confirm the publicly available mutation status in the NSCLC cell lines H838 and 
H1975 and to generate more detailed information, the cell lines were characterized by 
whole genome sequencing (WGS), RNA sequencing (RNAseq) and methyl-CpG 
immunoprecipitation (MCIp)-based methylome sequencing. The analysis was done by 
Stephen Krämer and Dr. Naveed Ishaque in the group of Benedikt Brors (DKFZ 
Heidelberg). All mutations reported in the literature were confirmed. However, no hyper-
methylation of the SOCS3 promoter region in the H838 cell line could be measured by 
MCIp. 
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Gene H838 H1975 
  type variation (PS) effect type variation (PS) effect 
TP53 SNV  p.E62* stop-gain SNV p.R273H unknown 
KRAS AMP   over-expression WT     
EGFR WT     SNV p.L858R, p.T790M 
activating, 
EGFR 
inhibitor-
resistant 
PIK3CA WT     SNV p.G118D activating 
PTEN WT     WT     
MET SNV p.I638L unknown AMP   over-expression 
CDKN2A DEL  inactivating SNV p.E69* stop-gain 
Table 2: Publicly available information of mutations in the NSCLC cell lines H838 and H1975. 
Abbreviations: PS: protein sequence, WT: wild type, SNV: single nucleotide variation, DEL: deletion, 
AMP: amplification, p protein;  
 
Moreover, SOCS3 mRNA levels could be detected by RNAseq and validated by qRT-
PCR (Figure 7A). Interestingly, the level of SOCS3 mRNA in H838 was even higher 
compared to the other NSCLC cell lines H1975 and H1650 and to the healthy lung 
alveolar epithelial cells type II (AECII, kindly provided by Prof. Heimo Mairbäurl, 
University Hospital Heidelberg) that are believed to be the origin of NSCLC. 
Additionally, the RNA analysis confirmed the over-expression of KRAS in H838 and an 
over-expression of TP53 in H1975 cells compared to the other two cell lines could be 
detected (Figure 7B). The mRNA levels of MET are higher in H1975 compared to H838 
but are comparable to H1650 although just H1975 harbors a higher gene copy number. 
In conclusion, the NSCLC cell lines H838 and H1975 were verified in their 
representative pattern of mutations for lung cancer and were therefore used for further 
analysis. 
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A.            B.  
     
Figure 7: Characterization of NSCLC cell lines. (A) Quantification of the RNAseq data of SOCS3 
mRNA in the NSCLC cell line H838 compared to H1975 and H1650 cells. The validation was performed 
by qRT-PCR in biological triplicates. The data is plotted relative to the healthy lung control (AECII, 
alveolar epithelial cells type II). (B) The RNAseq analysis of potential relevant genes with a high mutation 
frequency in lung cancer is shown in FPKM values for the NSCLC cell lines H838, H1975 and H1650. 
 
5.1.2 Establishment of optimized confluency conditions for long-term and short-
term experiments 
To ensure optimal conditions for experiments, different cell confluencies were seeded 
and cell proliferation was monitored over four days (Figure 8A). The cells were washed 
24 hours after seeding and kept in growth factor-depleted medium without serum over 
night  before the experiment started (t=0 days). The proliferation was measured using 
the CellTiter-Blue viability assay. The reduced signal intensity which corresponds to a 
reduced cell number at t=0 days compared to the time of seeding could be explained by 
the washing step. The lung cancer cells that were seeded in a very low confluency 
(≤40%) showed low proliferation rates whereas cells at a confluency between 40 and 
80% displayed an almost linear increase of proliferation until the maximum confluency 
was reached.  
Further, the influence of the ≥100% confluent state on the treatment efficiency was 
tested. Therefore, cells at a confluency of around 80% and fully confluent cells were 
treated with 10 U/ml erythropoietin (Epo) and the Epo-induced mRNA CISH was 
measured by qRT-PCR after 2 hours (Figure 8B). The 80% confluent condition showed 
compared to a confluency of ≥100% an increased mRNA induction upon treatment. 
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Thus, a confluency of 80% (~ 50,000 cells/cm2 growth area) was selected as optimal 
condition for experiments over maximal two days (short-term) before the maximum 
confluency is reached and a confluency of around 50% (~ 30,000 cells/cm2 growth area) 
was established for long-term experiments over several days (see also materials and 
methods). 
 
A. 
 
B. 
   
Figure 8: Optimization of experimental conditions. (A) The proliferation was measured with the 
CellTiter-Blue cell viability assay with different starting confluencies (see table on the right) of the NSCLC 
cell line H838 in a 96-well format. (B) The Epo-induced target gene CISH was measured by qRT-PCR in 
the H838 cell line in triplicates at a confluency of ~80% and ≥100% upon treatment with 0.1, 1 or 10 U/ml 
Epo (t = 2 hours). The data is shown relative to the untreated control (n=3). 
 
 
cells seeded/well 
(96-well plate) % confluent 
2500 12 
5000 24 
7500 36 
10000 48 
15000 72 
20000 96 
Results  27 
 
 
 
5.2 Cisplatin-induced apoptosis in NSCLC cell lines 
5.2.1 Time- and dose-dependent effect of cisplatin on NSCLC cell lines 
Although the pathway of intrinsic apoptosis induced by cisplatin is well known, 
mechanisms for resistance against this chemotherapeutic compound are poorly 
understood. Cisplatin is known to induce DNA damage in lung cancer followed by 
apoptosis when the concentration is high enough. To measure the changes in cell 
number over time, the sensitive CellTiter-Blue viability assay (Promega) was used. To 
test the possibility of cell number determination with the CellTiter-Blue assay, the H838 
cell line was seeded in different confluencies and the signal intensity was measured. In 
parallel, the cell number was counted with a Neubauer counting chamber. By plotting 
the signal intensity against the cell number, a direct linear correlation was observed 
(Figure 9A) that enabled the calculation of the cell number in further experiments when 
the signal intensity was known. 
 
A.                                                               B. 
     
Figure 9: (A) The signal intensity of 6 different cell concentrations of the NSCLC cell line H838 was 
measured with the CellTiter-Blue viability assay and plotted against the cell number that was counted in 
parallel with a Neubauer counting chamber. The average of the signal intensity of 10 wells (96 well plate) 
was calculated. (B) A dilution series of 100, 50, 25, 12.5, 6.25, 3.125, 1.562, 0.7813 mg/l cisplatin was 
applied on H838 cells. The signal intensity was measured with the CellTiter-Blue assay and the EC50 
values were calculated with the SigmaPlot software for 1, 2, 3, 5 and 7 days (table on the left). The upper 
and lower dashed lines depict the upper and the lower plateau of the sigmoidal curve that is used to 
determine the EC50 value. 
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To investigate the dose- and time-dependent effect of cisplatin on the NSCLC cell line 
H838, a dilution series of 100, 50, 25, 12.5, 6.25, 3.125, 1.562, 0.7813 mg/l cisplatin 
was applied according to the SOPs on 10,000 cells/well of a 96-well plate. The plates 
were incubated for one, two, three, five and seven days and the amount of viable cells 
was measured with the CellTiter-Blue viability assay. The effective concentration for 
50% of the treated cells (EC50) was calculated for different time points (graph and 
calculation shown representatively for the two days time point, Figure 9B). The NSCLC 
cell line showed an EC50 of 8.5 mg/l cisplatin at day one. For further analysis, the EC50 
that was detected after two days with a starting cell number of 10,000 cells/well (Figure 
9B) was selected to ensure the initiation of the apoptotic program but also allowing the 
possibility to start rescue mechanisms if cells are treated in parallel with components 
with a potential rescue effect. Moreover, this concentration is in the range of clinically 
relevant doses (see 4.3.1 Cisplatin-induced apoptosis). 
 
5.2.2 Rescue of cisplatin-induced apoptosis by MEK inhibition 
5.2.2.1 Influence of signaling pathway inhibitors on cisplatin-induced apoptosis 
To gain more insights into resistance mechanisms against chemotherapeutic 
compounds, the importance of PI3K/AKT and MAPK signaling pathways, which are 
known to be involved in cisplatin-induced apoptosis signaling [30, 31], was analyzed. 
Therefore, combined treatment of 5 mg/l cisplatin with inhibitors for PI3K (LY294002, 5 
µM), AKT1/2/3 (AKT inhibitor VIII, 5 µM) and MEK1/2 (U0126, 2.5 µM) was applied on 
the NSCLC cell line H838 for six days (Figure 10A) and cell viability was measured with 
the CellTiter-Blue assay. The growth factor-depleted cells were pre-incubated with the 
inhibitors for 60 minutes with appropriate concentrations [153, 154]. The inhibition of 
PI3K and AKT signaling pathway, which is known to play a role in survival and cell cycle 
regulation, resulted in a decreased proliferation but had no clear effect on the sensitivity 
to cisplatin. In contrast, inhibition of MEK activity resulted in a strong rescue effect if 
combined with cisplatin treatment. MEKi alone led to a slightly decreased proliferation 
that was not detectable before three days upon treatment. As inhibition of the MAPK 
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pathway seems to be the most promising method to perturb the cisplatin-induced 
apoptosis, the impact of the MEK inhibitors were studied in more detail. 
 
A. 
          
B.              C. 
           
                                     
Figure 10: Influence of inhibitors on cisplatin-induced apoptosis in the NSCLC cell line H838 
measured by CellTiter-Blue viability assay. (A) Left panel: the cell number is plotted over time upon 
inhibition of PI3K (LY294002, 5 µM), AKT1/2/3 (AKT inhibitor VIII, 5 µM) or MEK1/2 (U0126, 2.5 µM) 
compared to the untreated control. Right panel: 5 mg/l cisplatin was added to samples pre-treated for 60 
minutes with LY294002, AKT inhibitor VIII and U0126. (B) The H838 cell line was pre-treated for 60 
minutes with 2.5 µM MEKi U0126 and either 5 or 10 mg/l cisplatin was added. As controls, the cell 
number was determined with individual treatments of either 5 mg/l cisplatin, 10 mg/l cisplatin or 2.5 µM 
MEKi. Additionally to the untreated control, a DMSO control was included. (C) Test of the influence of 
MEKi pre-treatment times on cisplatin-induced apoptosis (10 mg/l cisplatin). The effect of pre-incubation 
with 2.5 µM for 60 minutes was compared to pre-incubation for 6 hours with MEKi and to simultaneous 
treatment of MEKi and 10 mg/l cisplatin. 
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To validate these findings and test the reproducibility of this effect, H838 cell line was 
growth factor-depleted and either treated with 2.5 µM MEKi or pre-treated for 60 
minutes with 2.5 µM MEKi before 5 or 10 mg/l cisplatin was added (Figure 10B). 
Individual treatment controls with 5 mg/l cisplatin or 10 mg/l cisplatin without U0126 
were included. Additionally to the untreated control, a DMSO control was measured to 
exclude effects of DMSO, in which the inhibitors are dissolved. Thereby, the DMSO 
concentration correlated to the DMSO content present upon applying 2.5 µM MEKi. The 
cells in the untreated control increased their cell number 3-4-fold within 6 days without 
the addition of growth factors. No effect of DMSO compared to the untreated control 
could be detected. The negative effect of MEKi on proliferation could not be reproduced. 
A dose-dependent effect of cisplatin could be observed. Treatment with 5 mg/l cisplatin 
resulted in a decreased cell number whereas a dose of 10 mg/l cisplatin led to a 
drastically reduced cell number compared to the untreated control. Pre-treatment with 
MEKi enabled the cells to completely counteract the treatment with 5 mg/l cisplatin and 
resulted in a higher cell number after five days compared to 5 mg/l cisplatin alone. The 
combination of 2.5 µM MEKi and 10 mg/l cisplatin did not affect cell proliferation but 
showed an increased proliferation after three days. The MEKi rescue effect on the 
higher dose of cisplatin was already visible after 24 hours, whereas the lower dose 
resulted only in an effect after three days of treatment. 
To study the influence of the MEKi pre-incubation time on the cisplatin sensitivity of 
H838 cells, the previously tested condition of 60 min pre-treatment was compared to an 
elongated pre-treatment time of 6 hours before adding 10 mg/l cisplatin and a 
simultaneous treatment of 2.5 µM MEKi and 10 mg/l cisplatin (Figure 10C). As controls, 
the cell numbers of H838 cells treated individually with 2.5 µM MEKi or 10 mg/l cisplatin 
were measured additionally to an untreated control. The proliferation of the untreated 
cells without the addition of growth factors could be reproduced. MEK inhibition showed 
no significant changes in the cell number compared to the untreated control. The cells 
that received 10 mg/l cisplatin alone reacted with a slight decline in cell number over 
time. The effect of pre-incubation for one hour with MEKi on the cisplatin sensitivity 
could be reproduced as well. The longer pre-incubation time of 6 hours with MEKi 
increased the rescue effect on the second day compared to cisplatin treatment alone 
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and was shown to be more effective after 3 days compared to one hour pre-treatment of 
MEKi. By simultaneous treatment of U0126 and cisplatin, the MEKi-induced rescue 
effect could not be detected before the third day of treatment but turned out to be less 
effective compared to pre-treatment with U0126. 
In conclusion, the inhibition of the activity of MEK with the MEKi U0126 resulted in a 
decreased cisplatin sensitivity of the NSCLC cell line H838. This MEKi rescue effect 
was even more prominent with higher cisplatin doses or increased pre-incubation times 
with MEKi before adding cisplatin. 
 
5.2.2.2 Influence of MEKi on protein levels of ERK 
ERK is the direct, and so far the only known, target of MEK [11] and can be activated 
upon cisplatin treatment [30]. To determine and quantify the effect of U0126 and 
cisplatin on ERK phosphorylation in the NSCLC cell line H838, the phosphorylated and 
total protein levels of ERK (ERK1+ERK2) were detected by quantitative immunoblotting 
(Figure 11A). To this aim, the H838 cell line was pre-treated for 60 minutes with 2.5 µM 
MEK inhibitor U0126 (MEKi) before adding 10 mg/l cisplatin (Cis). As controls, the 
pERK and ERK protein levels were determined for the untreated control (Ctrl) and 
individual treatments of 10 mg/l cisplatin or 2.5 µM U0126. Time points were taken 10 
minutes, 6 hours, 12 hours and 24 hours after the treatments.  
To determine how much ERK is phosphorylated relative to the total ERK level, the 
bands on the blot were quantified and the pERK-to-ERK-ratio was calculated (Figure 
11B). The untreated control showed a slight increase in ERK phosphorylation relative to 
the total ERK level within 24 hours. Cisplatin increased ERK phosphorylation already 
after 10 minutes of treatment compared to the starting level, with maximum at 6 hours 
and decreasing over time. In contrast, pre-treatment with 2.5 µM U0126 resulted in a 
reduced phosphorylation of approximately 50% compared to the untreated control. This 
inhibition effect of MEKi diminished over time and was not detectable any more after 24 
hours. Moreover, the analysis revealed that the combination of MEKi pre-treatment 
followed by cisplatin treatment showed comparable ERK phosphorylation as MEK 
inhibition alone.  
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Figure 11: Quantitative immunoblotting in the NSCLC cell line H838. This experiment was performed 
in triplicates and one representative example is shown. The cells were treated with 10 mg/l Cisplatin (Cis) 
and/or 2.5 µM MEK inhibitor U0126 (MEKi) or left untreated (Ctrl). After cell lysation, the proteins were 
separated by 10% SDS-PAGE, transferred to a nitrocellulose membrane and detected on the Image 
Quant LAS 4000 by chemiluminescence. (A) The phosphorylated and total ERK levels (ERK1+ERK2) 
were detected.  (B) The pERK to ERK ratio was calculated of the quantified bands. (C) The apoptosis 
marker cleaved caspase-3 and the housekeeper β-actin are shown. (D) Quantification of the cleaved 
caspase-3 relative to β-actin. 
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To further test whether the decreasing cell number of cisplatin-treated cells could be 
ascribed to apoptosis, but also to investigate if additional inhibition of MEK results in 
decreased apoptosis, the protein level of cleaved caspase-3 as an apoptotic marker 
was measured by quantitative immunoblotting (Figure 11C). To this aim, H838 cells 
were serum-starved and incubated with the same treatments described in Figure 11A. 
The quantified bands (Figure 11D) of the untreated control showed a very slight 
increase in cleaved caspase-3 levels over time. In contrast, chemotherapeutic treatment 
with 10 mg/l cisplatin resulted in the cleavage of caspase-3 visible at the 6 hour time 
point and was still detectable and even stronger after 24 hours. The incubation with 2.5 
µM MEKi U0126 led to moderate increase of active caspase-3 which was reached after 
6 hours and stayed constant afterwards in the time observed. The combination of pre-
treatment with 2.5 µM MEKi and 10 mg/l cisplatin showed comparable results as MEK 
inhibitor treatment alone. 
In conclusion, MEK inhibition increases cisplatin-induced phosphorylation of ERK and 
cleavage of caspase-3 in the NSCLC cell line H838. The combination of MEKi and 
cisplatin shows comparable results as MEK inhibition alone. 
 
5.2.2.3 Influence of MEKi on the cell cycle 
As shown in Figure 10A, inhibition of MEK activity can have an influence on 
proliferation of the NSCLC cell line H838. In combination with the observation that 
cisplatin targets fast dividing cells [30], it was hypothesized that the rescue mechanism 
of MEKi on cisplatin-induced apoptosis in NSCLC cells is connected to the regulation of 
the cell cycle.  
To test this, the length of the cell cycle phases were measured in H838 cells that stably 
express the FUCCI sensor (kindly provided by Dr. Sofia Depner) by live cell microscopy. 
The FUCCI system is a fluorescent protein-based system that employs both a red 
(mKate2) fluorescent protein fused to the cell cycle regulator Cdt1 (present in G1-
phase) and a green fluorescent protein (EGFP) fused to Geminin (present in S-, G2-, 
and M-phase) and thus enables the discrimination between the G0/G1- and the 
S/G2/M-phases (Figure 12A+B). 
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A. 
 
B.               C.    D. 
        
Figure 12: Time-lapse microscopy of the NSCLC the cell line H838 expressing the FUCCI sensor 
enables the measurement of the length of the cell cycle phases. (A) Two mother cells (yellow and 
blue arrows) were followed until dividing into two daughter cells (orange and green arrows). (B) The cell 
cycle phases were identified by phase-specific expression of EGFP and mKate2. (C) The cells were 
imaged with a confocal microscopy (Nikon Ti eclipse). The images of the time course were taken every 
20 minutes. The analysis of the microscopy data sets shows the changes in cell number upon single and 
combined treatment with 5 mg/l Cisplatin (Cis) and/or 2.5 µM MEKi (MEKi) in comparison to the untreated 
control (Ctrl). The experiment was performed twice. (D) The CellTiter-Blue viability assay of the wild type 
cell line H838 with the same treatments is shown in biological triplicates.  
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The cells were seeded with 50% confluency according to the SOPs, growth factor 
depleted, pre-treated with 2.5 µM MEK inhibitor U0126 (MEKi) and/or 5 mg/l cisplatin 
(Cis) or left untreated (Ctrl) (Figure 12C). The H838-FUCCI cells were imaged with a 
confocal microscopy (Nikon Ti eclipse). The images of the time course were taken every 
20 minutes over 72 hours. As expected, the cells of the untreated control proliferated 
whereas the cisplatin treatment induced apoptosis. The combination of MEKi pre-
tratment and additional cisplatin treatment resulted in an increased cell number 
compared to cisplatin treatment alone. However, the cells under the microscope 
showed decreased cell numbers if treated with cisplatin or MEK inhibitor compared to 
the CellTiter-Blue viablity assay (Figure 12C+D). Nevertheless, the rescue effect of 
MEKi on the cisplatin-induced apoptosis was detectable with both assays. 
By tracking the cells, mother and daughter cells could be followed and connected in a 
time-resolved manner to the cell cycle phases, cell divisions and apoptotic events. The 
cell tracking and the mathematical analysis of the microscopy data was performed by 
Dr. Carsten Maus in the group of Prof. Thomas Höfer (DKFZ Heidelberg).  
The analysis of the connection between the cell cycle phase in which the cells received 
cisplatin and the apoptotic events revealed that the cells of the untreated controls and 
the cells that were treated with MEKi did not show a clear preference for the cell cycle 
phase in which they went into apoptosis (Figure 13A). In contrast, the cisplatin-treated 
cells predominantly died in the block of the S/G2/M-phases. This was true for individual 
treatment with cisplatin or cisplatin in combination with MEK inhibition, where 82% and 
75% of all cells of the initial population that went into apoptosis died in the S/G2/M-
phases. 
It was further analyzed if the frequency of mitotic events was connected to the applied 
treatments (Figure 13B). Approximately 65% of the initial population of the untreated 
control underwent mitosis. These 65% were composed of approximately 50% of the 
cells that were in the G1/G1 cell cycle phase and approximately 80% in the S/G2/M 
phase of the whole initial population. Cisplatin treatment resulted in a reduced cell 
division rate of approximatly 20% of the initial population and the cells that were in the 
G1/G0 phase at the time of the treatment did not even divide any more. MEK inhibition 
decreased the mitotic events of cells that were treated during the G1/G0 cell cycle 
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phase in comparison to the untreated control. The combination of MEKi and cisplatin 
resulted in a slightly decreased mitosis rate of cells in the S/G2/M phase whereas cells 
that were in the G1/G0 phase at the time of the treatment did not undergo mitosis. 
 
A.     B.              C. 
                   
D.   
      
Figure 13: Quantitative analysis of the time-lapse 
microscopy data with the NSCLC cell line H838 
expressing the FUCCI sensor. The cells were 
imaged with a confocal microscopy (Nikon Ti 
eclipse). The images of the time course were taken 
every 20 minutes. The cells were treated with 5 mg/l 
cisplatin and/or 2.5 µM MEKi U0126 or left 
untreated. (A) Quantification of the percentage of 
apoptotic events in the different cell cycle phases of 
apoptotic events over time. (B) Frequency of mitotic 
events upon the different treatments connected to 
the cell cycle phase at the time of treatment. (C+D) 
Quantification of the cell cycle phase lengths upon 
the different treatments. (figure kindly provided by 
Dr. Carsten Maus) 
 
 
Moreover, the lengths of the cell cycle phases were determined for the different 
treatments (Figure 13C+D). The analysis showed that the untreated control showed an 
average G1/G0 cell cycle phase length of approximately 15 hours and an average 
S/G2/M cell cycle phase length of apprximately 10 hours. The chemotherapeutic drug 
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prolonged the S/G2/M-phases to approximately 50 hours but did not affect the length of 
the G1/G0 phase. Inhibition of MEK activity resulted in increased G0/G1 phase lengths 
and a slight elongation of the S/G2/M phase compared to the untreated control. The 
combination of MEKi and cisplatin treatment resulted in comparable cell cycle phase 
lengths like MEKi treatment alone.  
In conclusion, MEK inhibition was shown to result in a prolonged G0/G0 cell cycle 
phase in cisplatin-treated cells. As cisplatin was shown to mainly target cells in the 
S/G2/M phase, this might hint to an indirect rescue affect by giving the cell more time, 
for instance for DNA-repair, which results in an increased cell number. 
 
5.2.2.4 Influence of MEKi on gene expression 
As shown in Figure 11, MEK inhibitor U0126 inhibits cisplatin-induced phosphorylation 
of ERK on protein level and it is known that this can lead to a G1 arrest in fibroblasts 
and pancreatic cancer cell lines [14, 155] and activation of ERK is even required to 
enter the S phase [11-13]. Moreover, we could show that addition of U0126 to the 
cisplatin-treated NSCLC cell line H838 resulted in a beneficial effect induced by cell 
cycle arrest compared to chemotherapeutic treatment alone. To investigate how U0126 
alone and in combination with cisplatin influences the MAPK signaling and how this 
effects the cell cycle on RNA level, quantitative RT-PCR was performed (Figure 14). 
Moreover, it was tested whether MEK inhibition, additionally to cell cycle regulation, 
leads to counteraction of cisplatin-induced apoptosis by altered expression of pro- and 
anti-apoptotic genes. 
To this aim, the NSCLC cell line H838 was pre-treated for 60 minutes with 2.5 µM MEK 
inhibitor U0126 (MEKi) before 10 mg/l Cisplatin (Cis) was added. Moreover, individual 
treatments with 2.5 µM MEK inhibitor or 10 mg/l cisplatin were included additionally to 
an untreated control (Ctrl). Time points were taken 0, 1, 2, 4, 8, 12, 24 and 48 hours 
after the treatments and the quantified mRNA levels were displayed as fold change 
relative to the untreated control at the beginning of the time course (t=0h). Classical 
MAPK target genes, transcription factors that are known to be induced by MAPK, cell 
cycle regulators and mRNAs that are known to be involved in apoptosis signaling were 
measured. 
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Figure 14: Quantitative RT-PCR of the NSCLC cell line H838 treated with 10 mg/l cisplatin (Cis) and/or 
pre-incubation for 60 minutes with 2.5 µM MEK inhibitor U0126 (MEKi) or left untreated (Ctrl) of (A) 
classical MAPK target genes, (B) transcription factors that are known to be induced by MAPK, (C) cell 
cycle regulators and (D) mRNAs involved in apoptosis signaling (n=3).  
 
First, the inhibitory effect of MEKi and cisplatin alone and in combination on the 
classical MAPK targets EGR1, EGR3 and DUSP5 were measured (Figure 14A). The 
mRNA level stayed constant over time in the untreated control. Upon MEK inhibition, 
EGR1 and EGR3 mRNA levels were comparable to the untreated control within the first 
24 hours and increased 48 hours after the treatment. DUSP5 mRNA was slightly down-
regulated upon MEKi treatment within the first 24 hours. As expected, the 
chemotherapeutic agent induced the expression of all three MAPK target mRNAs. The 
inhibition of the cisplatin-activated MAPK pathway target genes by MEKi was detectable 
over the whole time course. 
Next, the transcription factors JUN, FOS and ELK1 that are activated by the RAS–RAF–
MEK–ERK-cascade [156] were analyzed (Figure 14B). No mRNA expression changes 
could be observed for the untreated control. MEK inhibition resulted in a slight increase 
of JUN and ELK1 mRNA levels compared to the untreated control. Upon cisplatin 
treatment, JUN and FOS mRNAs were upregulated within the first 8 hours of the time 
course and showed afterward a sustained expression, whereas ELK1 mRNA was not 
induced before 48 hours compared to the untreated control. A pre-treatment with the 
MEKi U0126 decreases the cisplatin-induced expression of the transcription factor 
mRNAs analyzed. 
Furthermore, the impact of MEKi and cisplatin alone and in combination on cell cycle 
regulators CCNA1 (CyclinA1), CCNB1 (CyclinB1), CCND1 (CyclinD1), CCNE1 
(CyclinE1), CDKN1A (p21) and CDKN1B (p27) was verified (Figure 14C). The 
untreated control did not show any changes in the expression of the mRNAs analyzed. 
The expression of the cyclin mRNAs with MEKi was slightly increased at the later time 
points compared to the untreated control. Interestingly, CDKN1A (p21) and CDKN1B 
(p27), which are known to induce cell cycle arrest in the G1 phase, were the only cell 
cycle genes tested that were rapidly increased within the first hours followed by a 
sustained expression with U0126 alone. Cisplatin compared to the untreated control 
also induced CDKN1A mRNA but not before 8 hours and CDKN1B mRNA 24 hours 
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after the treatment. All cyclins analyzed were induced by cisplatin compared to the 
untreated control with CCNA1 and CCNB1 being induced 24 hours and CCND1 and 
CCNE1 being induced already 12 hours upon the treatment. This effect could be 
decreased by additional pre-incubation with MEKi. The combined treatment of MEKi 
and cisplatin showed the same effect on CDKN1A and CDKN1B mRNA expression as 
MEK inhibition alone. 
Finally, mRNAs connected to the apoptotic process, such as TP53, M2MD and Bcl-2 
family members [37, 49, 50] (Figure 14D) were analyzed. The mRNA level stayed 
constant over time in the untreated control. MEK inhibition downregulated the anti-
apoptotic BCL2 mRNA compared to the untreated control. Also cisplatin treatment led to 
a downregulation of BCL2 but to a larger extend. The pre-incubation with MEKi did not 
affect the cisplatin-induced decrease of BCL2 mRNA expression. MDM2 mRNA, which 
is known to be able to downregulate p53, was upregulated 24 hours after the treatment 
with cisplatin compared to the untreated control and showed a slight decreased 
expression if cisplatin was combined to U0126. The TP53 mRNA expression did not 
change over within the time observed for all treatments tested. 
In conclusion, these results are consistent with the previously shown MEKi-induced G1 
cell cycle phase elongation. We could also show that U0126 induced CDKN1A (p21) 
and CDKN1B (p27) that are known to regulate G1 arrest. The BCL2 mRNA down-
regulation upon MEK inhibition is also in line with the previously shown MEKi-dependent 
cleavage of caspase-3. It can be further excluded that the effect of MEKi on the cisplatin 
sensitivity is regulated by the anti-apoptotic BCL2 mRNA as MEKi could not counteract 
its cisplatin-dependent downregulation.  
 
5.2.2.5 Time- and dose-dependent effect of different clinically relevant MEK 
inhibitors (MEKi) on cisplatin-induced apoptosis 
To better understand the effect of MEK inhibitors on NSCLC and to show that the effect 
of MEKi U0126 is specific, further experiments with other MEK inhibitors were 
performed. Therefore, additionally to MEKi U0126, clinically relevant MEK inhibitors like 
selumetinib (AZD6244), Cl-1040 (PD184352), PD0325901 and trametinib 
(GSK1120212) were tested. First, the efficiency of these MEK inhibitors was determines 
Results  41 
 
 
 
qualitatively by measuring the phosphorylation of the MEK downstream targets ERK1 
and ERK2 (Figure 15).  
 
A. 
 
  
B. 
 
 
 
 
 
Low dose [µM] High dose [µM]
Selumetinib 2.5 10
Cl-1040 1 5
PD0325901 0.01 0.1
Trametinib 0.01 0.1
U0126 2.5 10
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Figure 15: Time- and dose-dependent effect of different MEK inhibitors (MEKi) on the NSCLC cell 
line H838. (A) The cells were pre-treated for 60 minutes with a MEKi dilution series  of 0, 0.001, 0.01, 
0.1, 1, 2.5, 5, 10 or 20 µM before 40 ng/ml HGF was added. After cell lysation, the proteins were 
separated by 10% SDS-PAGE, transferred to a nitrocellulose membrane and ERK and pERK were 
detected on the Image Quant LAS 4000 by chemiluminescence. Low MEKi doses (half-effective MEK 
inhibition) and high MEKi doses (complete MEK inhibition) were determined qualitatively. (B) CellTiter-
Blue viability assay of the H838 cell line upon different treatments; 0, 5 or 10 mg/l cisplatin combined with 
high or low MEKi doses. The DMSO control with 0.1% DMSO corresponds to the DMSO level of 10 µM 
MEKi. The experiment was performed in biological triplicates. 
 
 
To this aim, the NSCLC cell line H838 was pre-incubated for 60 minutes with different 
doses (0, 0.001, 0.01, 0.1, 1, 2.5, 5, 10, 20 µM) of U0126, selumetinib (AZD6244), Cl-
1040 (PD184352), PD0325901 and trametinib (GSK1120212) before adding 40 ng/ml 
HGF to fully activate the MAPK cascade. The cells were lysed after 10 minutes which 
corresponds to the maximum peak level of ERK phosphorylation [153]. Quantitative 
immunoblotting of pERK and ERK revealed large differences in the efficiency of the 
inhibitors. Selumetinib treatment was comparable to U0126 with a half-effective dose 
(low dose MEKi) of approximately 2.5 µM and a complete inhibition (high dose MEKi) of 
ERK phosphorylation at a concentration of 10 µM. Interestingly, PD0325901 and 
trametinib turned out to be around 100-fold more efficient compared to selumetinib and 
U0126 by completely inhibiting ERK phosphorylation at already 0.1 µM and the half-
effective dose for both was determined to be around 0.01 µM. The inhibitor CI-1040 
showed a half-effective dose of 1 µM and an almost complete inhibition at a 
concentration of 5 µM. 
To study the influence of half-effective (low dose MEKi) and complete (high dose MEKi) 
inhibition of MEK activity on cisplatin-induced apoptosis, the NSCLC cell line H838 was 
pre-treated for 60 minutes with the different MEK inhibitors (high and low doses MEKi, 
lower right panel (Figure 15A) followed by the treatment with either no, 5 or 10 mg/l 
cisplatin (Figure 15B). All MEK inhibitors were dissolved in DMSO and were available 
in the same stock concentration of 10 mM. As the maximal MEKi concentration used 
was 10 µM resulting in a final concentration of 0.1% DMSO, all conditions were adjusted 
to this concentration including the DMSO control. The cell viability was measured using 
the CellTiter-Blue assay.  
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The MEK inhibitors alone led to a slightly decreased proliferation compared to the 
DMSO control. Dependent on high and low doses, the effect of MEKi on cisplatin 
treatment with 5 mg/l cisplatin differed in efficiency. The half-effective inhibition with all 
MEK inhibitors led to an increased cell number whereupon selumetinib turned out to be 
the most effective one and U0126 the weakest showing the rescue effect not before the 
third day. 
The complete inhibition of the MEK activity combined with 5 mg/l cisplatin resulted in a 
clear effect for all inhibitors compared to the DMSO control with selumetinib again being 
among the top candidates. Increasing the cisplatin concentration to 10 mg/l resulted in 
an effect comparable to 5 mg/l but the cells in the DMSO control died already on the 
second day. In particular, the cells with a full inhibition of MEK activity showed a clear 
advantage compared to the DMSO control. Again, selumetinib treatment but 
interestingly also U0126 especially at later time points revealed its rescue potential. 
PD0325901, which was shown in Figure 15A to be quite efficient in MEK inhibition by 
quantitative immunoblotting, turned out to have less rescue potential if combined with 
high cisplatin concentrations. 
In conclusion, not only the MEKi U0126 but also clinically relevant MEK inhibitors were 
shown to be able to decrease the cisplatin sensitivity of the NSCLC cell line H838. 
Furthermore, this effect of the MEK inhibitors became more prominent if the MEK 
activity was completely inhibited with a high MEKi dose compared to a low MEKi dose 
that resulted just in a half-effective inhibition. 
 
To sum up, cisplatin treatment could be verified to activate the RAS–RAF–MEK1/2–
ERK1/2 cascade. The cisplatin-induced phosphorylation of ERK and the upregulation of 
the ERK targets EGR1, EGR3, DUSP5, JUN, FOS and ELK1 was counteracted by 
additional pre-treatment with MEKi. Moreover, the study revealed that MEKi was not 
only able to prolong the G1/G0 cell cycle phase but also upregulated CDKN1A mRNA 
which is known to induce G1 arrest. This might hint to an indirect rescue affect by giving 
the cell more time, for instance for DNA-repair or cisplatin disposal, which results in an 
increased cell number. 
 
Results  44 
 
 
 
5.3 Role of Epo in NSCLC 
Patients suffering from chemotherapeutic-induced anemia can be medicated either with 
blood transfusion or Erythropoiesis-stimulating agents (ESA) such as erythropoietin 
(Epo) to support erythropoiesis and thus increase the number of red blood cells. 
Unfortunately, recent studies have shown that Epo can have tumor stimulating effects 
and EpoR expression in NSCLC is associated with poor survival [89, 90]. For this 
reason, the treatment of patients with Epo in the context of cancer-related anemia is 
discussed controversially [84, 94-96]. 
 
5.3.1 Rescue of cisplatin-induced apoptosis by Epo treatment  
To analyze the biological effect of Epo and its receptor (EpoR) on lung cancer cells, 
which is known to trigger cyto-protective and anti-apoptotic effects [84, 157], NSCLC 
cell lines were screened for EpoR expression. H838 cells significantly express EpoR 
mRNA compared to healthy lung alveolar epithelial type II cells (AECII) and other lung 
cancer cell lines, e.g. H1650, H1975, H1944 and H2030. Moreover, detectable protein 
amounts of the receptor that can be phosphorylated upon Epo-β stimulation could be 
measured in low (P5) and high (P25) passage numbers of H838 cell line (Figure 
16A+B). As the sequencing also showed that H838 expresses the wild type receptor, 
this cell line was selected for further experiments. Additionally, H838 cells that stably 
over-expresses the Epo receptor (kindly provided by Sofia Depner) (Figure 16C) were 
used to mimic a situation for increased signaling levels upon Epo treatment. This was 
shown by increased expression levels of the EpoR signaling target gene CISH upon 
stimulation already at low Epo doses (Figure 16D). To further test the effect of Epo 
treatment on H838 cell line, the cells were serum-starved and left either untreated or 
treated with the clinically relevant cisplatin dose of 5 mg/l and/or 10 U/ml Epo over four 
days and the cell number was determined by the CellTiter-Blue viability assay (Figure 
16E). The cells in the untreated control increased their cell number 4-fold within 4 days 
without the addition of growth factors. Epo treatment showed a comparable proliferation 
rate to the untreated control. Cells that were incubated with 5 mg/l cisplatin alone 
showed no significant proliferation and a slight decrease of cell number over time 
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whereas additional treatment with Epo resulted in a significant rescue effect giving an 
advantage to parallel-treated cells. 
 
 
A.         B.             C. 
            
D.                                          E. 
      
Figure 16: The NSCLC cell line H838 contains the functional Epo receptor (EpoR). (A) EpoR mRNA 
expression was measured by qRT-PCR in lung carcinoma cell lines compared to healthy alveolar 
epithelial cells type II (AECII) (n=3). (B) H838 cells in different passage numbers (P5 and P25) were 
serum-starved and either left untreated or stimulated with 10 U/ml Epo-β  for 10 minutes. After cell 
lysation, quantitative immunoprecipitation of EpoR was performed followed by a 10% SDS-PAGE, a 
transfer to a nitrocellulose membrane and EpoR and pEpoR detection on the Image Quant LAS 4000 by 
chemiluminescence. (C) qRT-PCR measurements of the EpoR mRNA expression level in H838 and 
H838-EpoR (n=3).  (D) The Epo-induced target gene CISH was measured by qRT-PCR (n=3) in the cell 
lines H838 and H838-EpoR upon stimulation with different Epo doses. (E) Measurement of the cell 
number of H838 cells with the CellTiter-Blue viability assay with or without stimulation with 10 U/ml Epo or 
additional treatment with 5 mg/l cisplatin (n=3). 
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Moreover, this recue effect of Epo on cisplatin-treated cells could also be monitored by 
live-cell imaging microscopy (Figure 17) in a preliminary experiment. Therefore, the 
NSCLC cell line H838-EpoR was stably transfected with the CasperGR FRET 
(fluorescence resonance energy transfer)-based sensor (kindly provided by Dr. Sofia 
Depner) which enables the measurement of cleaved caspase-3 quantitatively in a time-
resolved manner in living cells [158]. The sensor consists of green (GFP) and red 
fluorescent proteins (RFP) connected by the linker containing the caspases-3 cleavage 
sequence DEVD which leads to FRET between these fluorescent proteins. Caspase-3 
activation leads to the cleavage of the DEVD sequence resulting in FRET elimination 
which is detectable in the changing ratio of green to red. The CasperGR-containing cells 
were treated either singly or with a combination of 5 mg/l cisplatin, Epo-β in high dose of 
500 U/ml or low dose of 10 mg/l or left untreated (Figure 17A). As positive control, 10 
µM staurosporine was used that induces apoptosis quite rapidly. Indeed, the low dose 
of Epo resulted in a rescue effect if combined with cisplatin compared to cisplatin alone. 
Moreover, the high dose of 500 U/ml Epo almost completely counteracted the effect of 
cisplatin with only a slight increase in caspase-3 activation. Interestingly, Epo even 
reduced the cleaved caspase-3 signals if combined with staurosporine compared to 
staurosporine alone. The maximum peak of caspase-3 activity with cisplatin alone was 
reached at around 24 hours. After 24 hours, almost all cells with cisplatin underwent 
apoptosis (Figure 17B), which explains why the signal levels decreased afterwards 
(Figure 17A). 
Compared to the CellTiter-Blue experiment where some cells survived several days with 
Cisplatin alone, all cells were dead after two days in the microscopy experiment. This 
could be explained by the additional stress induced by laser energy of the microscope 
and the glass surface of the dish where the cells were seeded on.  
In conclusion, Epo treatment was shown to decrease the cisplatin sensitivity in the 
NSCLC cell line H838 that expresses the functional Epo receptor. This effect was 
shown to be Epo dose-dependent. 
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Figure 17: Rescue effect of Epo on cisplatin-treated H838-EpoR cells measured with the CasperGR 
sensor by live-cell imaging. The cells were imaged on an environment-controlled microscope (Zeiss 
LSM 710). (A) The caspase-3 activity was measured by the CasperGR FRET-based sensor. The cells 
were treated either singly with Epo-β in high dose of 500 U/ml or low dose of 10 mg/l or or with a 
combination of 5 mg/l cisplatin or left untreated. 10 µM staurosporine was used as positive control for 
apoptosis. (B) Microscopy images at the start of the time course measurement (t = 2h) and the maximum 
peak of active caspase-3 (t= 24h) showing the apoptotic effect of cisplatin (bar = 20 µm). 
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5.3.2 EpoR signaling in NSCLC and primary erythroid progenitor cells 
To better define the risk of Epo treatment upon chemotherapy-induced anemia for the 
patients, EpoR signaling in NSCLC cells needs to be understood in more detail. To 
identify differences in the Epo-induced signaling to primary erythroid progenitor cells 
and to dissect the complexity of the EpoR system, a mathematical model based on 
ordinary differential equations (ODEs) for the lung cancer cell line H838 and primary 
erythroid cells was established. 
As already shown in Figure 16, the NSCLC cell line H838 expresses not only EpoR 
mRNA but also contains the functional receptor which can be phosphorylated upon Epo 
stimulation. Furthermore, the rescue effect mediated by Epo on cisplatin-induced 
apoptosis in the H838 and the EpoR overexpressing H838-EpoR cell line (Figure 16 
and Figure 17) demonstrated that Epo has the potential to influence the signaling in 
cancer cells. Therefore, H838 and H838-EpoR were selected as NSCLC model systems 
for EpoR signaling. As erythroid model system, the Epo-dependent primary erythroid 
mouse CFU-Es (mCFU-Es, colony forming unit erythroid) were selected, as human 
CFU-E cells are very limited. 
 
5.3.2.1 Establishment of a mathematical model for the Epo-induced signaling in 
lung cancer cells and primary erythroid progenitor cells  
The EpoR signaling pathway in CFU-Es has previously been described with a 
mathematical model [62]. The ODE-based mathematical model is divided into three 
submodules that represent the cell compartments plasma membrane, cytoplasm and 
nucleus. As model input, a constant Epo concentration was assumed as it was shown 
that the effect of the Epo depletion is marginal. The complex formation and activation 
status of the Epo receptor and JAK2 was considered with a full activation in two steps to 
be able to describe the effect of the phosphatase. In the first step, EpoR at the plasma 
membrane undergoes a conformational change upon ligand binding and activates the 
pre-bound tyrosine kinase JAK2. In the second step, the activated JAK2 phosphorylates 
EpoR. These processes can be reversed by the phosphatase. The pJAK2pEpoR-
complex is now able to bind and phosphorylate the transcription factor STAT5 in the 
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cytoplasm. In consequence, pSTAT5 translocates into the nucleus (npSTAT5) where it 
activates the transcription of the negative regulators CISH (CIS protein) and SOCS3 
that were modeled with a delay in their production. CIS inhibits STAT5 activation by 
binding to EpoR, whereas SOCS3 directly binds to the kinase domain of JAK2 and 
EpoR, thereby inhibiting tyrosine-kinase activity. A protein tyrosine phosphatases (PTP) 
also negatively regulates the receptor-JAK2-complex. 
 
 
 
Figure 18: Quantitative dynamic model. The Process diagram of the quantitative dynamic model of the 
Epo-induced JAK2/STAT5 signaling pathway was drawn with the cell designer software. The binding of 
the ligand Epo to its receptor results in the phosphorylation of JAK2 and EpoR (EpoRpJAK2). STAT5 is 
recruited by pEpoR and phosphorylated by pJAK2, dimerizes and translocates to the nucleus where it 
starts the transcription of the negative feedback regulators CIS and SOCS3.  
Results  50 
 
 
 
As a starting point for the cancer cell model in this study, the already existing 
quantitative dynamic model in CFU-Es [62] was used. The modeling was performed by 
the theoretical cooperation partner Bernhard Steiert in the group of Prof. Jens Timmer 
(Freiburg University). The mathematical model (Figure 18) is represented as process 
diagram showing the network structure including transcription, translation, state 
transition, catalysation and inhibition but also transport processes. The phosphorylation 
status shows if the protein is available in its active or inactive form.  
 
To adapt the CFU-E-model [62] to the lung cancer cells, biologically-motivated pathway 
extension and adaptions for H838 and H838-EpoR cells were made. For instance, SHP-
1, which is a lineage-specific protein-tyrosine phosphatase (PTP) that is mainly 
expressed in the hematopoietic system could not be detected by RNAseq analysis in 
H838 cells. Thus, SHP-1 was replaced in the model by the more general term “PTP”. 
Further, the volumes of the cytoplasm and the nucleus of H838 cells were measured 
and compared to the mCFU-E data [62]. To this aim, H838 cells that stably express the 
green fluorescent protein (H838-GFP, kindly provided by Dr. Sofa Depner) were stained 
with Hoechst (H33342) and imaged on an environment-controlled microscope (Zeiss 
LSM 710). The images of single cells were acquired in the blue and green channel 
applying the z-stack method with a distance of 2 µm between the images. The Imaris 
software (Bitplane) was used for surface reconstruction that enables the calculation of 
the volume (Figure 19).  
The quantification of the total cell volume was generated by using the GFP data and the 
volumes of the nuclei by Hoechst staining. 24 H838-GFP cells were measured and the 
total cell volume was calculated. Compared to CFU-E cells, the cancer cells have a 
much smaller nucleus in relation to the cytoplasm with a nucleus-to-cytoplasm ratio of 
0.28 +/-0.007. The nuclei of CFU-Es constitute more than half of the cells with a 
nucleus-to-cytoplasm ratio of 0.69 [62]. 
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Figure 19: Measurement of cell type-specific parameters. H838-GFP cells were stained with Hoechst 
(H33342) and imaged on an environment-controlled microscope (Zeiss LSM 710). The volumes of the 
nucleus and the total cell volume were measured by the z-stack method, displayed and quantified with 
the Imaris software. The nucleus-to-cytoplasm ratio was calculated as depicted below the image. 
 
5.3.2.2 Generation of quantitative time-resolved data 
To calibrate the model with quantitative time-resolved data of the cancer cells, CISH 
and SOCS3 mRNA was measured upon stimulation with Epo-β by quantitative RT-PCR 
in the NSCLC cell lines H838 and H838-EpoR (Figure 21, black dots). The basal 
expression of SOCS3 and CISH mRNAs was tested with 1 µg/ml actinomycin D that 
inhibits the synthesis of new mRNA (Figure 20). Without freshly synthesized mRNA, the 
levels decreased over time for both mRNAs in both cell types. 
Quantitative immunoblotting and mass spectrometry was applied for protein 
measurements of (p)EpoR, (p)JAK2 and (p)STAT5 (measured by Florian Salopiata). 
For the CFU-Es, the previously described data [62] was used. The whole model 
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consists of 36 kinetic, 143 scaling ans offset and 16 error parameters describing 57 
conditions with 1117 data points.  
 
         
Figure 20: Measurement of the basal level of CISH and SOCS3 mRNA by qRT-PCR. The H838-EpoR 
and CFU-E cells were treated with 1 µg/ml actinomycin D (ActD) to inhibit new mRNA synthesis. This 
experiment was performed in triplicates and one representative example is shown. 
 
5.3.2.3 Model selection and calibration 
In the next step, the model was calibrated based on the previously generated 
experimental data by testing whether the model can describe the data of the NSCLC 
cell lines H838 and H838-EpoR additionally to CFU-Es. Therefore, three model 
strategies were tested (Figure 21). The model fits are shown representatively for CISH 
and SOCS3 mRNA and pEpoR, pSTAT5, total STAT5 (tSTAT5) protein levels (protein 
levels were measured by Florian Salopiata).  
In the 1st strategy, all parameters were chosen to be different for all cell types 
suggesting a situation where the cell types have no parameters in common. This model 
could describe all data sets (Figure 21, green curve). On the other hand, some 
parameters might be estimated to similar values due to too many degrees of freedom. 
However, the exact value might not be identifiable. 
The 2nd strategy was to assume no cell type-specific parameters (Figure 21, purple 
curve). As the model could not describe the data, this model was rejected. 
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Finally, the 3rd strategy was used to identify the number of cell type-specific parameters 
that are necessary to describe the data best (Figure 21, orange curve). The best 
description is defined as smallest number of parameters necessary to most accurate 
describes the data. Thereby, this minimal (=parsimonious) model fit should describe the 
data to a similar extend as the model of the 1st strategy. All these criteria could be 
fulfilled with the minimal model. Therefore, this model was selected as the best model. 
 
 
Figure 21: Model selection and calibration: The whole model consists of 36 parameters describing 57 
conditions with 1117 data points. Representatively, just the model fits for a couple of species is shown 
here for the three cell types H838, H838-EpoR and CFU-Es. This includes the EpoR target genes CISH 
and SOCS3 measured by qRT-PCR and pEpoR, pJAK2 and pSTAT5 protein data measured by 
quantitative immunoblotting. The dots represent experimentally measured data, solid lines depict the 
three applied model strategies in purple (no cell type-specific parameters), green (only cell type-specific 
parameters) and orange (minimal model). 
 
5.3.2.4 Identification of differences in Epo-induced signaling 
The minimal model was shown to describe the data best. The parameters were not only 
optimized to describe the data as accurate as possible, but also cell type-specific 
differences were penalized using the L1 penalty approach [159-162]. Optimizing for 
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these two criteria, it could be shown that the majority of model parameters are identical 
and just 8 out of 36 parameters were predicted to be cell type-specific in the cell types 
H838/H838-EpoR and CFU-Es (Figure 22A). These parameters are the activation of 
EpoR by JAK2 (EpoRActJAK2), the activation of JAK2 by Epo (JAK2ActEpo), the 
deactivation of the JAK2-EpoR-complex by PTP (JAK2EpoRDeaPTP), the activation of 
PTP by EpoR (PTPActEpoR), the SOCS3 inhibition rate (SOCS3Inh), the SOCS3 
mRNA turnover rate (SOCS3RNATurn), the STAT5 import rate (STAT5Imp) and the 
deactivation rate of nuclear STAT5 (nSTAT5Dea).  
The profile likelihood analysis revealed that 6 out of the 8 identified parameters that 
were predicted to be different were identifiable and the other two showed a 
unidentifiability (Figure 22B). These two are the deactivation rate of the receptor-kinase 
complex by the PTP and the activation rate of the PTP by the receptor 
(JAK2EpoRDeaPTP and PTPActEpoR). If one, in this case the deactivation parameter 
was selected, was fixed to a certain value, the difference between these two parameters 
(PTPActEpoR_rel) was identifiable (Figure 22B, lower right panel). At least one 
parameter of these is cell-type specific but both could be cell-type specific. 
 
Most of the predicted differences between the cell types could be explained by 
biological differences of the erythroid and the lung cancer cell background. The reason 
for the specific STAT5 import rate (STAT5Imp) in CFU-Es compared to H838/H838-
EpoR could be found in the different nucleus-to-cytoplasm-ratios. The deactivation rate 
of nuclear STAT5 (nSTAT5Dea) is different due to different phosphatases or different 
amounts of phosphatase. The differences in the activation of JAK2 by Epo 
(JAK2ActEpo), the activation of the receptor by its kinase (EpoRActJAK2) and inhibition 
by SOCS3 of the receptor complex (SOCS3Inh) could possibly be explained due to a 
cell-specific amount of JAK2 and the ratio of JAK2- to EpoR-molecules in H838 and 
CFU-Es. As no SHP1 is available outside the hematopoietic system, the differences for 
the deactivation of the JAK2-EpoR complex by PTP or the activation of PTP by EpoR 
(JAK2EpoRDeaPTP and PTPActEpoR) are not surprising. 
The only predicted difference between the cell types that could not be explained is the 
SOCS3 mRNA turnover rate (SOCS3RNATurn).  
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Figure 22: Identification of cell type-specific differences. (A) Identification of differences using the L1 
penalty. The parameters are indicated with shades of red (lower in H838/H838-EpoR) to blue (higher in 
H838/H838-EpoR). (B) Profile likelihood analysis of the predicted parameter specificities for the different 
cell types. All parameters were identifiable except for the deactivation rate of the receptor-kinase complex 
by the PTP and the activation rate of the PTP by the receptor (JAK2EpoRDeaPTP and PTPActEpoR). 
The difference of these parameters (PTPActEpoR-relative) is larger than zero and identifiable (lower right 
panel). 
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5.3.2.5 Experimental validation of the predicted cell type-specific SOCS3 mRNA 
turnover rate 
The SOCS3 mRNA turnover rate is predicted to be much lower in CFU-Es compared to 
the lung cancer cells (Figure 22, lower panel on the left). In the next step, this model 
prediction was experimentally validated. The turnover rate is defined as the degradation 
over time or the mRNA stability.  
To enable the measurement of the RNA degradation experimentally, actinomycin D 
(ActD) treatment was applied at the peak of the signaling dynamic to inhibit further 
mRNA synthesis. The time of the peak was predicted to be different for the two cell 
types. The maximal expression of SOCS3 mRNA in CFU-Es was predicted to be after 
60 minutes whereas in H838-EpoR the predicted dynamics were faster and reached the 
peak after 30 minutes upon Epo treatment. The CISH mRNA dynamics that was 
predicted to have the same parameters in the different cell types was used as control.  
To validate these predictions, the SOCS3 and CISH mRNA was measured upon the 
treatment with Epo or ActD additionally to Epo by qRT-PCR (Figure 23). Both mRNAs 
in H838-EpoR and CFU-Es showed reduced mRNA levels if the cells were treated with 
ActD. In H838-EpoR, ActD treatment resulted in even lower SOCS3 mRNA level 
compared to the starting concentration. 
These results confirmed that the selected model can describe the experimental data 
and predict differences in SOCS3 mRNA half-lives in the lung cancer and the erythroid 
cells. In conclusion, this mathematical tool can be used to reveal differences between 
the two cell types which might enable targeting one cell type with a certain drug and 
leave the other one unaffected. 
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Figure 23: Experimental validation of the cell type-specific SOCS3 turnover rate by qRT-PCR. The 
H838 cells were stimulated with 10 U/ml Epo-β Epo at t=0 min (dashed black line) and new mRNA 
synthesis was inhibited with the treatment of 1 µg/ml actinomycin D (ActD, dashed green line) at the 
predicted peak of SOCS3 mRNA (t=30 min) (green and black dots). CFU-E cells were stimulated with 5 
U/ml Epo-α and treated with 1 µg/ml ActD at t=60 min. The SOCS3 mRNA level was measured with qRT-
PCR and CISH mRNA was measured in parallel as control (green and black dots). The model prediction 
is depicted as black or green line. Shaded areas indicate estimated errors. This experiment was 
performed in triplicates and one representative example is shown. Model predictions were performed by 
Bernhard Steiert. 
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To sum up, the NSCLC cell line H838 expresses significant amounts of Epo receptor 
that can be phosphorylated upon stimulation with Epo. It was further shown that Epo 
treatment decreased the cisplatin sensitivity of H838 cells for clinically relevant cisplatin 
concentrations. In conclusion, the presence of EpoR in NSCLC could pose a risk for 
lung cancer patients receiving a combined treatment of cisplatin-based chemotherapy 
and Epo. In order to assess the risk that might be connected to Epo treatment in more 
detail and to dissect the complexity of EpoR signaling, a mathematical model of Epo-
induced signaling was established that was able to identify differences between the 
NSCLC cell line H838 and the actual therapy target, the erythroid progenitor cells. The 
SOCS3 mRNA turnover rate was among the predicted cell type-specific parameters. It 
could be experimentally validated by qRT PCR that SOCS3 mRNA is more stable in 
CFU-Es than in H838 cells. In conclusion, the study suggests a higher and more 
sustained pSTAT5 level in H838 cells compared to CFU-Es, that is known to be 
connected to survival of CFU-Es [62]. 
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5.4 TGF-β signaling in NSCLC cell lines 
NSCLC is characterized by a high metastasizing rate. The transforming growth factor 
beta (TGF-β) induces epithelial-to-mesenchymal transition (EMT) [118-122] which is the 
key for tumorigenesis, migration and invasion. Moreover, high TGF-β levels are 
correlated with poor prognosis in lung cancer [125, 127]. Although EMT is quite well-
characterized, so far no drug, small molecule or inhibitor has been identified that is able 
to target this pathway and reduce the metastatic properties of lung cancer. Therefore, 
the influence of TGF-β on NSCLC cell lines had to be tested to gain more detailed 
information about how signal is transduced in NSCLC cell lines.  
 
5.4.1 TGF-β is able to induce TGF-β signaling in NSCLC cell lines 
As the first step, it was investigated whether TGF-β is able to induce downstream 
signaling in NSCLC cell lines. This was tested by the measurement of the 
phosphorylation status of the downstream targets SMAD2 and SMAD3 upon TGF-β 
stimulation. The NSCLC cell lines H838, H1975 and H1650 were seeded according to 
the SOPs. The cells were either serum-starved (-FCS-TGF-β), left in serum-containing 
medium (+FCS-TGF-β) or treated with 1 ng/ml TGF-β for 60 minutes (-FCS+TGF-β). 
The cells were lysed and prepared for quantitative immunoblotting (Figure 24A). 
Separate immunoprecipitations (IP) were performed for the detection of the TGF-β 
signaling molecules SMAD2, SMAD3 and SMAD4 followed by immunoblotting against 
phosphorylated and total species. The housekeeper β-actin was used as a loading 
control for the total cell lysates (TCL). For all cell lines, the same amount of protein was 
used for the analysis of the different proteins. The results demonstrated that TGF-β 
stimulation led to phosohorylation of the downstream components SMAD2 and SMAD3 
in all three cell lines. Interestingly, H838 cells contained low levels of total SMAD3 and 
pSMAD3 in comparison to the other cell lines. The level of SMAD4 was comparable for 
all the cell lines tested. H1975 cell line that showed the highest level of pSMAD3 and 
total SMAD3, was selected for further analysis.  
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Figure 24: Measurement of TGF-β signaling in NSCLC cell lines. (A) Quantitative immunoblotting of 
the TGF-β-stimulated NSCLC cell lines H838, H1975 and H1650. The cells were serum-starved (-FCS/-
TGF-β) or left in medium with FCS (+FCS/-TGF-β) or treated with 1 ng/ml TGF-β for 60 minutes (-
FCS/+TGF-β). After cell lysation, immunoprecipitation was performed for SMAD2, SMAD3 and SMAD4 
followed by 10% SDS-PAGE. The proteins were transferred to a nitrocellulose membrane and detected 
on the Image Quant LAS 4000 by chemiluminescence. β-actin was used as loading control for the 
individual cells lines. This experiment was performed in triplicatws and one representative example is 
shown. Abbreviations: IP: immunoprecipitation, TCL: total cell lysate, FCS: fetal calf serum. (B) 
Quantitative RT-PCR of the TGF-β target gene SMAD7 in the cell line H1975. The cells were serum-
starved and either treated with 10 ng/ml TGF-β or left untreated. The mRNA levels are shown relative to 
the starting point of the time course (t=0h). 
 
In the next step, the cell line H1975 was tested for the activation of TGF-β downstream 
signaling on mRNA level. For this purpose, the most prominent TGF-β target gene 
SMAD7 [99, 163] was monitored over time. H1975 cells were seeded according to the 
SOPs and stimulated with 10 ng/ml TGF-β or left untreated. Samples for the time points 
0, 1, 2, 4, 6, 12, 24 and 48 hours after the treatment were taken and total RNA was 
extracted using TRIzol. The SMAD7 mRNA was detected by qRT-PCR and depicted 
relative to the starting point (t = 0 hours) (Figure 24B). The untreated control did not 
show any change in SMAD7 mRNA expression over time. However, upon TGF-β 
treatment SMAD7 mRNA expression was significantly increased with a maximum 
expression peak within the first hours. However after six hours, the SMAD7 level 
decreased but did not decline to the starting level even within the 48 hours of 
observation. 
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These results demonstrated that TGF-β was able to activate TGF-β signaling in the 
NSCLC cell lines H838, H1975 and H1650 and also to induce the mRNA expression of 
the TGF-β target gene SMAD7 at least in H1975. 
 
5.4.2 Expression analysis of TGF-β-dependent genes in the NSCLC cell line 
H1975 
To analyze the gene expression pattern in H1975 after TGF-β stimulation, a mRNA time 
course experiment with different time points (0, 0.5, 1, 2, 4, 6, 12, 24 and 48 hours) was 
performed and analyzed by a mRNA microarray (GeneChip 2.0 ST, Affimetrix). One 
replicate of each time point was used for the analysis except of the time points 0, 24 
and 48 hours which were measured in triplicates. The microarray data analysis was 
performed by the theoretical cooperation partners Dr. Hauke Busch and Dr. Melanie 
Börries (Freiburg University). To identify biological processes that were significantly 
regulated by TGF-β in comparison to the untreated control, the expression profiles were 
analyzed using the GO (gene ontology) database. 
The analysis is shown as a heatmap (Figure 25) for TGF-β-induced downregulated or 
upregulated processes. The color code depicts the p-value. The first block of genes 
downregulated by TGF-β (Figure 25A) is connected to mitosis and cell cycle. This 
included genes involved in the general mitotic process, mitotic cell cycle, cell division 
and the activity of cell cycle checkpoints. Within the first hour, these processes are 
downregulated, followed by a phase where no significant changes in expression could 
be observed. However, 6 hours upon the treatment with TGF-β the genes connected to 
mitosis were again downregulated for the rest of the observed time period. 
The second block of downregulated processes connected to mitosis and cell cycle were 
just downregulated 6 hours after the TGF-β treatment without an initial significance peak 
within the first hour. These processes included activity of the spindle apparatus, 
telomere maintenance via recombination, DNA gap filling, mitotic cell cycle spindle 
assembly checkpoint, mitotic chromosome condensation, M/G1 transition of mitotic cell 
cycle and G1/S transition of mitotic cell cycle. 
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The processes connected to DNA repair and DNA replication, such as the activity of 
DNA damage checkpoint, double-strand break repair, ATP-dependent DNA helicase 
activity, mismatch repair, nucleotide-excision repair, DNA-directed DNA polymerase 
activity, double-strand break repair via homologous recombination, DNA repair in 
general, DNA replication and DNA strand elongation involved in DNA replication are 
downregulated after 6-12 hours upon TGF-β treatment. Although the p-value differs for 
different processes, all expression changes compared to the untreated control are 
significant. 
TGF-β also upregulated several biological processes (Figure 25B). This includes the 
organization of the extracellular matrix and cell adhesion, which had the highest p-value 
for upregulation 6 hours after the stimulation with TGF-β. More distinct but still 
significant over time, processes connected to adhesion and filament organization, such 
as skeletal system development, collagen binding, cytoskeleton organization, gap 
junction and cell adhesion in general were upregulated with TGF-β. Moreover, cell 
migration and epithelial to mesenchymal transition (EMT) are upregulated. 
To sum up, among the downregulated biological processes, mitosis, cell division, cell 
cycle and DNA repair and replication were detected. In contrast, TGF-β upregulated 
processes were connected to adhesion, cell junctions, migration and EMT. 
The experimental validations of several genes involved in the TGF-β pathway and in 
EMT processes such as SMAD7, TGFBR1 and TGFBR2, ZEB1, SNAI1 (Snail), SNAI2 
(Slug), FN1 (Fibronectin), CDH1 (E-cadherin), CDH2 (N-cadherin), VIM (Vimentin) and 
SKIL (SnoN) were performed by qRT-PCR (Figure 29). 
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Figure 25A.      Biological processes downregulated upon TGF-β treatment 
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Figure 25B.    Biological processes upregulated upon TGF-β treatment 
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Figure 25: Heatmap of significantly responding genes to TGF-β treatment annotated to (A) 
downregulated or (B) upregulated biological processes (GO analysis). The NSCLC cell line H1975 was 
treated with 10 ng/ml TGF-β or left untreated. A mRNA microarray (GeneChip 2.0 ST, Affimetrix) was 
performed for the time points 0, 0.5, 1, 2, 4, 6, 12, 24 and 48 hours. The terms on the right denote the 
most significant GO biological processes. The color code depicts the p-value (Figure kindly provided by 
Dr. Hauke Busch and Dr. Melanie Börries).  
 
5.4.3 Validation of selected target genes induced by TGF-β in NSCLC cell lines 
To verify mRNAs that were found to be upregulated in the NSCLC cell line H1975 by 
microarray analysis, selected mRNA were measured by qRT-PCR (Figure 26). The 8 
selected candidates included mRNAs that are known to be involved in MAP kinase 
signaling (MAP3K4, MAP3K9), TGF-β/SMAD signaling (SMURF1, KLF10), EMT 
(SNAI1), survival (XIAP), transcription factors (JUNB) and the cell cycle (CDKN1A). 
The validation of mRNA dynamics for the first 12 hours was performed by qRT-PCR in 
biological triplicates with a time course for the NSCLC cell lines H1975 and additionally 
in the NSCLC cell line H838. To this aim, the cells were seeded according to the SOPs, 
growth factor depleted and lysed 0, 1, 2, 3, 4, 6, 8 and 12 hours upon the treatment with 
1 ng/ml TGF-β. An untreated control was measured in parallel for all time points. 
The results showed similar dynamics as observed by microarray. It could be confirmed 
that all mRNAs were rapidly upregulated within the first hours upon TGF-β treatment in 
H1975 cells compared to the untreated control. In general, TGF-β treatment was more 
effective for all mRNAs tested in H1975 cells compared to H838. TGF-β-dependent 
expression of mRNAs was found to be more reduced in H838 cells. Moreover, no 
significant changes in the expression levels were detectable for MAP3K9 and XIAP 
mRNA in H838. 
In sum, all selected mRNA candidates could be confirmed to be TGF-β target genes at 
least in the NSCLC cell lines H1975 and H838. The H1975 cells showed higher mRNA 
expression upon stimulation with TGF-β compared to H838 cells, which is in line with 
the phosphorylation pattern of SMAD and SMAD3 proteins measured for both cell lines 
shown in Figure 24. In conclusion, the TGF-β-induced signaling cascade could be 
activated in the H1975 cell line to a higher extend compared to the cell line H838. 
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Figure 26: Validation of TGF-β-inducible mRNAs by qRT-PCR in the NSCLC 
cell lines (A) H1975 and (B) H838. The classical TGF-β targets KLF10 and 
SMURF1, the EMT marker SNAI1, the pro-survival factor XIAP, the MAPK 
pathway members MAP3K9 and MAP3K4 and the cell cycle inhibitor CDKN1A are 
shown representatively. The study was performed in triplicates. 
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5.4.4 The TGF-β pseudoreceptor BAMBI is downregulated in NSCLC  
One of the key problems in lung cancer is early spread. EMT, which can be induced by 
TGF-β, is known to be involved in the development of the metastasis properties of cells. 
One factor that can negatively influence the TGF-β pathway is the TGF-β 
pseudoreceptor BAMBI that was shown to be epigenetically silenced in bladder cancer 
[115] and is absent in breast cancer [116]. As our cooperation partner Dr. Sebastian 
Marwitz in the group of Prof. Torsten Goldmann (Research Center Borstel, Division of 
Clinical and Experimental Pathology) could show that BAMBI protein is absent in lung 
adenocarcinoma patient samples (immunohistochemistry), BAMBI was selected for 
further analysis. 
To determine the mRNA expression level of BAMBI and EMT genes in lung 
adenocarcinoma tumors, matched pairs of tumor and tumor-free lung of 9 patients 
(cDNA kindly provided by the Research Center Borstel) was tested by qRT PCR 
(Figure 27A). The analysis revealed that not only BAMBI, but also the mRNA of TGF-β 
receptors TGFBR1 and TGFBR2 and SMAD7 were downregulated in all tested 
adenocarcinoma tumors. Interestingly, also the mRNA for the EMT genes SNAI1 
(Snail), SNAI2 (Slug), ZEB1, VIM (Vimentin), FN1 (Fibronectin) was downregulated in 
the analyzed adenocarcinomas. CDH2 (N-cadherin) was found to be downregulated in 
almost all tumors tested. CDH1 (E-cadherin) and SPP1 mRNA were upregulated in the 
tumor sample compared to its matching tumor-free lung. 
To analyze if the BAMBI downregulation observed in the adenocarcinoma tissue 
samples of patients could be reflected in NSCLC cell lines, the mRNA expression level 
of BAMBI was monitored using  quantitative RT-PCR in the cell liens H838, H1650 and 
H1975 and compared to the BAMBI expression level in healthy lung alveolar epithelial 
type II cells (AECII) (Figure 27B). All three cell lines showed significantly lower levels of 
BAMBI mRNA compared to AECII (two-tailed t-test, p<0.001 = ***). The cell lines H838 
and H1650 expressed approximately half as much mRNA with 0.5-fold expression for 
H838 and 0.62-fold expression for H1650 compared to the healthy control. The cell line 
H1975 showed a dramatic downregulation of BAMBI mRNA with an expression level of 
0.015-fold lower than AECII. 
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Figure 27: (A) Matching pairs of lung adenocarcinoma tumor and tumor-free lung of 9 patients. The 
levels of the EMT-related mRNAs were measured by qRT-PCR. One blue dot represents one 
adenocarcinoma tissue sample of a patient. The black line depicts a ratio of 1, representing comparable 
amount in the tumor and the tumor-free sample. (B) Relative quantification by qRT-PCR of BAMBI mRNA 
in the NSCLC cell lines H838, H1650 and H1975, compared to the healthy AECII cells. p<0.001 = *** 
(two-tailed t-test), n=3. 
 
5.4.5 BAMBI reconstitution decreases the expression of TGF-β-dependent genes 
in the NSCLC cell line H1975 
The TGF-β pseudoreceptor BAMBI was found to be downregulated in lung 
adenocarcinoma tumors and also in the NSCLC cell lines H838, H1650 and H1975. To 
investigate whether this loss of BAMBI expression influences TGF-β-induced signaling, 
BAMBI was reconstituted in the NSCLC cell line H1975 to mimic a “healthy” situation. 
To this aim, the NSCLC cell line was transfected 
with the TET-On system and thus expressed either 
BAMBI coupled to GFP (H1975-BAMBI-GFP) or as 
control GFP alone (H1975-GFP) if induced with 
doxycycline (kindly provided by Dr. Sofia Depner). 
The reconstitution was effective with a 5349-fold 
increased expression of BAMBI mRNA in H1975-
BAMBI-GFP compared to H1975-GFP (Figure 28). 
To determine the effect of the reconstitution of 
BAMBI in the NSCLC cell line H1975, the H1975-
BAMBI-GFP and H1975-GFP cells were seeded 
according to the SOPs, treated with 5 µl/ml doxycylin 
(DOX) for 24 hours, serum-starved in DOX-
containing medium for approximately 16 hours and 
treated with 0.1 ng/ml TGF-β. The TGF-β-induced expression of the EMT-involved 
mRNAs SMAD7, TGFBR1 and TGFBR2, ZEB1, SNAI1 (Snail), SNAI2 (Slug), FN1 
(Fibronectin), CDH1 (E-cadherin), CDH2 (N-cadherin), VIM (Vimentin) and SKIL (SnoN) 
were analyzed for the time points 0, 1, 4, 24 and 48 hours by qRT-PCR (Figure 29).  
 
Figure 28: Measurement of the 
BAMBI mRNA expression by qRT-
PCR in the cell lines H1975-
BAMBI-GFP and H1975-GFP 
upon the treatment with 5 µl/ml 
doxycylin (n=3) . 
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Figure 29: Reconstitution of BAMBI in the NSCLC cell line H1975 with the TET-On system (H1975-
BAMBI-GFP, depicted in red) in comparison to the control cell line H1975-GFP (depicted in blue) upon 
stimulation with 0.1 ng/µl TGF-β. Signaling dynamics for the EMT-involved mRNAs SMAD7, TGFBR1 and 
TGFBR2, ZEB1, SNAI1 (Snail), SNAI2 (Slug), FN1 (Fibronectin), CDH1 (E-cadherin), CDH2 (N-cadherin), 
VIM (Vimentin) and SKIL (SnoN) were analyzed for the time points 0, 1, 4, 24 and 48 hours by qRT-PCR. 
The data is shown relative to the GFP-control at t = 0 hours. The experiment was performed in triplicates. 
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The reconstitution of BAMBI resulted in a reduced mRNA starting level for FN1, SKIL, 
VIM, TGFBR1, TGFBR2 (t-test, p ≤ 0.001) and CDH1 0.05 (t-test, p ≤ 0.05). All mRNAs 
of the H1975-GFP control cell line were upregulated upon stimulation with TGF-β. 
BAMBI reconstitution reduced TGF-β-induced mRNA expression although a similar 
overall dynamics of mRNA expression was observed except for CDH1, TGFBR2 and 
ZEB1 mRNA which was no longer inducible upon TGF-β treatment in H1975-BAMBI-
GFP cells. 
 
Taken together, the negative regulator of TGF-β signaling BAMBI was shown to be 
downregulated in adenocarcinoma tumors and the NSCLC cell lines H1975, H838 and 
H1650. The reconstitution of BAMBI resulted in decreased expression of EMT markers 
such as Snail, Slug, Fibronectin, E-cadherin, N-cadherin and Vimentin.  
In conclusion, BAMBI expression is negatively correlated to the potential for EMT and 
thus metastasis in NSCLC. BAMBI is thereby suggested to act as a tumor suppressor in 
NSCLC.  
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6. Discussion 
6.1 Effect of MEKi on cisplatin-induced apoptosis in NSCLC cell lines 
6.1.1 Cisplatin activates the RAS–RAF–MEK–ERK cascade and induces 
apoptosis in NSCLC cells 
As standard of care, NSCLC patients are treated with platinum-based chemotherapeutic 
drugs [22], such as cisplatin. In this study, the effect of cisplatin on NSCLC cell lines 
was tested. The NSCLC cell line H838 was selected as model system for NSCLC as it 
harbors a representative pattern of mutations for lung cancer. 
It was shown by quantitative immunoblotting, that cisplatin treatment led to an increased 
phosphorylation of ERK1 and ERK2 within 6 hours compared to the untreated control. 
ERK1 and ERK2, that are known to be direct and the only targets of its upstream kinase 
MEK [11], were also shown to be phosphorylated by treatment with cisplatin in the lung 
adenocarcinoma cell line A549 and the NSCLC cell line H460 [34]. The activation of 
ERK was not only reported for lung cancer cells but also for several other cell types, 
reviewed by Basu et al. [30]. It was further shown that EGR1 and EGR3 mRNAs were 
upregulated 2 hours after cisplatin treatment in ovarian cancer cells [164] and EGR1 
mRNA after 24 hours in osteosarcoma cells [165]. However, little is known about 
cisplatin-induced mRNA expression in NSCLC cells. To this aim, the cisplatin-induced 
upregulation of the mRNA expression of MAPK target genes EGR1, EGR3 and DUSP5 
was confirmed by quantitative qRT-PCR in the NSCLC cell line H838. 
Moreover, cisplatin was verified to mediate apoptosis in the NSCLC cell line H838. This 
was expected, as cisplatin is an FDA-approved chemotherapeutic agent for NSCLC and 
Tsai et al. already showed by using the tetra-zolium dye colorimetric assay that cisplatin 
induces apoptosis in H838 cells [166]. The time- and dose-dependent effect of cisplatin 
on the cell viability of H838 cells was confirmed with the colorimetric CellTiter-Blue 
viability assay. Furthermore, the protein level of cleaved caspase-3 as an apoptotic 
marker was established by quantitative immunoblotting in H838 cells. A slight increase 
of cleaved caspase-3 was observed after 6 hours and a strong increase after 12 hours 
of treatment with cisplatin. Moreover, it was shown by qRT-PCR that cisplatin treatment 
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resulted in downregulation of anti-apoptotic factor BCL2. This confirmed the initiation of 
the apoptotic program in the NSCLC cell line H838 upon cisplatin treatment. 
Furthermore, an analysis by live cell imaging with H838 cells that express the FUCCI 
cell cycle sensor revealed that cisplatin affects primarily cells in the S/G2/M cell cycle 
phases in which DNA is replicated and cell division occur. This was not surprising as 
cisplatin is known to bind to purine bases and to intercalate in DNA which interferes with 
cell division and consequently leads to induction of apoptosis in dividing cells [30]. 
 
6.1.2 Pre-incubation with MEKi decreases the cisplatin sensitivity of NSCLC cells 
Although cisplatin-based chemotherapy is initially rather effective, many cancer patients 
relapse with a cisplatin-resistant disease [23, 53]. Several mechanisms contributing to 
therapy resistance are discussed in the literature, such as an activating mutation in the 
MAPK pathway [15].  KRAS for instance, is with 17% one of the most frequently 
mutated genes in lung cancer [16] and 30% of the NSCLC were found to harbor RAS 
mutations  Therefore, several MEK inhibitors (MEKi) that block signaling downstream of 
MEK, have been tested in clinical trials also in combination with chemotherapeutic 
drugs [15] (ClinicalTrials.gov, Identifier: NCT01809210).  
In this study, the influence of MEKi on the effect on NSCLC cells of treatments with 
clinically relevant cisplatin doses was examined. By quantitative immunoblotting, it was 
shown that pre-incubation for 60 minutes with MEKi U0126 of the NSCLC cell line H838 
resulted in a decreased cisplatin-induced ERK phosphorylation. Moreover, MEKi was 
found to counteract the expression of the MAPK target genes EGR1, EGR3 and DUSP5 
upon cisplatin treatment in H838 cells. 
Interestingly, MEKi not only influenced cisplatin-induced signaling, but also affected 
cellular processes. For instance, live cell imaging with the FUCCI cell cycle sensor 
revealed that MEK inhibition alone or in combination with cisplatin resulted in an 
elongated G1 cell cycle phase in H838 cells. Moreover, CDKN1A mRNA, that is known 
to induce a G1 cell cycle arrest, was found to be upregulated upon stimulation with 
MEKi. This suggests that MEK inhibition might induce G1 arrest in the NSCLC cell line 
H838. This would be in line with literature where it was reported that MEK inhibition can 
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lead to a G1 arrest in fibroblasts and pancreatic cancer cell lines [14, 155] and 
activation of ERK is even required to enter the S phase [11-13]. 
The study further revealed that pre-treatment with MEK inhibitor U0126 is able to rescue 
H838 cells from cisplatin-induced apoptosis. This effect could be measured with the 
CellTiter-Blue viability assay and by microscopy-based live cell imaging. Moreover, 
reduced levels of cleaved of caspase-3 were obtained by quantitative immunoblotting 
for the combined treatment of cisplatin and MEKi compared to cisplatin treatment alone. 
However, the cisplatin-mediated downregulation of BCL2 mRNA could not be 
counteracted with MEKi. Furthermore, CellTiter-Blue measurements revealed that the 
MEKi-mediated rescue effect on cisplatin-induced apoptosis could be increased with 
elongated MEKi pre-incubation times. This effect could also be monitored in the NSCLC 
cell line H838 for the clinically relevant MEK inhibitors selumetinib (AZD6244), Cl-1040 
(PD184352), PD0325901 and trametinib (GSK1120212) [15]. 
A MEKi-mediated rescue of cisplatin-induced apoptosis was already observed in mouse 
liver cells [167], mouse renal cells [168], human testicular germ cell tumor cell lines [39], 
human hepatocellular carcinoma [169] and in the human lung cancer cell lines A549 
and H460 [34]. In contrast, in human ovarian cancer cells U0126 treatment in addition to 
cisplatin resulted in increased apoptosis rates [170]. It was also demonstrated that the 
elevated expression of RAS, an upstream component of the MEK-ERK signaling 
pathway, was connected with enhanced sensitivity to cisplatin [36]. Moreover, HeLa cell 
variants that were selected for cisplatin resistance, showed reduced activation of ERK 
following platinum treatment [36]. In sum, these studies showed that decreased 
signaling via the RAS–RAF–MEK1/2–ERK1/2 cascade was correlated to decreased 
cisplatin sensitivity. However, there are also contrary observations about for the role of 
ERK in influencing cell survival of cisplatin-treated cells. It was shown that the MEK1-
specific inhibitor PD98059, sensitizes human melanoma cells [171], human ovarian 
carcinoma cell lines [172, 173], human pancreatic cancer cells [174] and human cervical 
carcinoma cells [175] to cisplatin-induced apoptosis. 
Different possibilities are conceivable how the MEK inhibitor was able to decrease the 
sensitivity of the NSCLC cells to cisplatin. For instance, the inhibition of the MAPK 
pathway with MEKi might either lead to a downregulation of pro-apoptotic molecules or 
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an upregulation of anti-apoptotic molecules as the RAS–RAF–MEK–ERK pathway is 
known to be involved in the regulation of pro- and anti-apoptotic Bcl-2 family members 
in the lung adenocarcinoma cell line A549 [176] and pancreatic cancer cells [174]. This 
possibility might not be very likely as it was shown by qRT-PCR that MEKi could not 
counteract the cisplatin-mediated downregulation of BCL2 mRNA. 
The studies rather suggest a rescue mechanism in which the NSCLC cell lines is 
arrested in the G1 cell cycle phase and can therefore not be targeted by cisplatin, as it 
was shown that the chemotherapeutic agent attacks cells in the S/G2/M phase. 
Furthermore, the cells might also benefit from the increased time for the repair of 
damaged DNA strands.  
In conclusion, MEK inhibitor treatment leads to an indirect rescue effect on cisplatin-
induced apoptosis in the NSCLC cell line H838. The study shows that MEKi treatment in 
combination with cisplatin-based chemotherapy poses a potential risk for lung cancer 
patients.  
 
6.2 Role of Epo-induced signaling in NSCLC cell lines 
6.2.1 Epo treatment decreases the cisplatin sensitivity of the EpoR-expressing 
cell line H838 
Lung cancer patients often suffer from cisplatin-induced anemia [177, 178]. Anemia is 
characterized by a decrease in the amount of erythrocytes or the amount of hemoglobin 
in the blood. The symptoms are caused by the lower oxygen levels in the blood and 
may include fatigue, shortness of breath or a general weakness and often come along 
with reduced quality of life. A toxicity grading system, including the grades mild (grade 
1), moderate (grade 2), serious/severe (grade 3) or life threatening (grade 4), was 
established by the World Health Organization [178]. Anemia has to be treated in grade 
3 and 4 (≤6.5-7.9 g hemoglobin /dl blood), as at this point not only  quality of life is 
impaired but also further planned chemotherapeutic cycles have to be dose-decreases 
or even cancelled. One possible treatment against anemia is thereby blood transfusion. 
Unfortunately, blood transfusions carry several risks, such as a viral or bacterial 
infection, acute hemolytic reactions, delayed hemolytic reactions and transfusion-related 
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acute lung injury [178-182]. Therefore, the erythropoietin-stimulating agent Epo was 
suggested as preferred treatment as it decreases chemotherapy-induced anemia in 
patients [183-187]. Unfortunately, recent studies have shown that Epo can have tumor 
stimulating effects [89] and Epo and EpoR co-expression is shown to be associated with 
poor survival of non-small cell lung cancer patients [90]. The expression of EpoR on 
mRNA and protein level was reported for several cell types. Hardee et al. reviewed the 
expression levels of EpoR in several other tumor types and cancer cell lines of different 
origins including bladder, breast, the female reproductive tract, the gastrointestinal tract, 
head and neck, hematologic, kidney, liver, lung, melanoma, nervous system, 
pancreatic, prostate, sarcoma and thyroid [188]. However, also the specificity of 
antibodies for EpoR, e.g. the Santa Cruz antibody C20 (catalogue number SC-695) [97, 
189], and consequently the proof for EpoR expression was discussed controversially 
[98]. 
In this study, the NSCLC cell line H838 was selected as model system to enable the 
analysis of the biological effect of Epo and its receptor on NSCLC cells. Dunlop et al. 
already described the EpoR expression in H838 cells and showed that Epo binding 
activates the three pathways JAK2/STAT5, RAS/ERK and PI3K/AKT [91]. It was 
confirmed by qRT-PCR and quantitative immunoblotting that H838 cells express 
significant amounts of Epo receptor. Moreover, the EpoR was shown to be functional as 
it was phosphorylated upon stimulation with Epo. 
Interestingly, Epo decreased the sensitivity of H838 cells to cisplatin. The analysis with 
the CellTiter-Blue viability assay showed a clear increased cell number for the combined 
treatment of Epo and cisplatin compared to cisplatin treatment alone. This rescue effect 
could also be observed by live cell imaging with a sensor for active caspase-3 under the 
microscope and was even shown to be dependent on the Epo dose. High Epo doses 
completely counteracted the cisplatin-induced activation of caspase-3. The applied 
cisplatin concentration was thereby in a range of clinically relevance. 
However, Epo was already shown to reduce the sensitivity to cisplatin of several cancer 
cells for cisplatin-induced apoptosis [190], including renal cell carcinomas [157, 191], 
melanoma [192], cervical cancer cells [193] and ovarian cancer cell lines [194]. 
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Phosphorylated STAT5A might be a key regulator of the Epo-induced rescue of 
cisplatin-induced apoptosis in lung cancer. Bittorf et al. showed that erythroleukemic cell 
lines lacking STAT5 docking sites in Epo receptors, have a diminished ability for the 
mediation of anti-apoptotic signals [195]. Moreover, STAT5 was reported to activate the 
anti-apoptotic factor Mcl-1 in B cell development [61] and anti-apoptotic Bcl-2 family 
members Bcl-2 and Bcl-xL in erythroid progenitor cells [84, 196-198] and myeloid 
leukemia [199]. 
To sum up, the EpoR-expressing NSCLC cell line H838 was shown to be less sensitive 
for cisplatin in clinically relevant doses upon treatment with Epo. In conclusion, the 
combined treatment of cisplatin-based chemotherapy and Epo might pose a risk for 
NSCLC patients with tumors expressing EpoR.  
 
6.2.2 A mathematical model of the Epo-induced signaling pathway predicts 
differences between NSCLC cell line H838 and erythroid progenitor cells 
As the intention of Epo treatment in the case of chemotherapy-related anemia is to 
target the erythroid system, to focus of this study was on the comparison of the 
activation of JAK2/STAT5 signaling in H838 cells and in primary erythroid cells (CFU-E). 
To be able to analyze the complex EpoR networks dynamics in both cell types, a 
dynamic pathway model was applied.  
EpoR signaling has already been described using a systems biology approach. Becker 
et al. [79] focused on the receptor level of EpoR signaling in BaF3-EpoR cells, a murine 
proB cell line that expresses high EpoR levels. The applied model contains parameters 
for receptor mobilization, recycling, and turnover. It was shown that after EpoR binds its 
ligand, the EpoR-Epo complex is internalized and degraded followed by a 
replenishment of the receptor from intracellular receptor pools [79]. It was previously 
shown by Yoshimura et al. that only a small proportion of EpoR is present on the cell 
surface and the majority is located in intracellular receptor pools [200]. Bachmann et al. 
[62] worked on the JAK2/STAT5 signaling pathway that is activated upon Epo binding 
and the specific function of the negative feedback regulators CIS and SOCS3 in murine 
CFU-Es. The applied mathematical model contains information about the processes at 
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the membrane, in the cytoplasm and the nucleus upon ligand binding. In CFU-Es, EpoR 
signaling upon Epo binding is essential for survival, proliferation and differentiation. It 
was further shown that there is a direct correlation of cell survival and the integrated 
response of STAT5 in the nucleus [62].  
In this study, the JAK2/STAT5 dynamic pathway model established by Bachmann et al. 
[62] was used as starting point and adapted to the NSCLC cell lines H838 and the EpoR 
overexpressing cell line H838-EpoR that was included to mimic a lung cancer situation 
with high EpoR expression in tumor cells. The mathematical model was further adapted 
to the lung cancer cells lines. This included the protein-tyrosine phosphatase SHP-1 
that was replaced by the more general term “PTP” as SHP1 was shown by RNAseq to 
be absent in H838 cells. However, this might not be true for all NSCLC cell lines, 
indicated by recent publications that found SHP-1 transcripts in epithelial cancer cells 
[201] including epithelial ovarian cancer [202] As there is strong evidence that NSCLC 
cells derived from alveolar epithelial cells type II (AECII) [2-5], some other NSCLC cell 
lines might express SHP-1. Cao et al. also detected SHP-1 in the lung cancer cell line 
A549 [203]. 
For model calibration, quantitative time-resolved data of the NSCLC cell lines H838 and 
H838-EpoR was measured using three different experimental techniques. The time-
resolved protein dynamics and the initial values were detected by quantitative 
immunoblotting. The quantitative mass spectrometry was applied to determine the 
absolute phosphorylation degree of STAT5 and qRT-PCR was performed to determine 
the mRNA dynamics of SOCS3 and CISH. Together with the CFU-E data taken from 
Bachmann et al. [62], the model was calibrated using the data of the different cell types. 
As the aim was to identify differences between the cancer cells and the erythroid 
system, the emphasis was placed on the identification of cell type-specific parameters. 
Therefore, different model strategies were applied to test how many parameters have to 
be different to be able to describe the data. The discrepancy between a fitted model and 
a data set, also called the goodness of fit, was quantified by the chi-square value [204, 
205]. The best model predicted 8 cell type-specific parameters for both cell types. All 
differences could be explained except of the SOCS3 mRNA turnover rate. A qRT-PCR 
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analysis validated that the SOCS3 mRNA was more stable in CFU-Es compared to the 
NSCLC cell lines.  
One possible mechanism for the cell type-specific SOCS3 mRNA turnover rate might be 
a cell type-specific expression level of miR-203, that was shown to specifically target 
and downregulate SOCS3 in keratinocytes [206], hepatocytes [76] and epidermal 
progenitors [207]. Moreover, miR-203 expression was correlated to higher SOCS3 
levels and increased cisplatin resistance in breast cancer cells [75]. Another hypothesis 
for the higher SOCS3 mRNA turnover rate in  the NSCLC cells would be an increased 
activation of the MAP kinase p38, that is known to be able to stabilize SOCS3 mRNA by 
binding to its AU-rich elements [73, 208].  
In this study, the applied mathematical was shown to be a useful tool that was able to 
pinpoint differences between the NSCLC cell line H838 and erythroid progenitor cells, 
e.g. the SOCS3 mRNA turnover rate. SOCS3 levels might be a potential marker for cell 
survival as it negatively targets STAT5 activity that is known to correlate with increased 
survival rates. The direct correlation of pSTAT5 levels and survival was already shown 
for B cell development and leukemia and primary erythroid cells [61, 62]. 
In conclusion, this model strategy can also be generalized and applied as a tool for the 
identification of pathway differences in other cell types or for different pathways. 
Thereby, potential therapeutic targets, e.g. tumor cells, might be identified. 
 
6.3 Role of TGF-β signaling in NSCLC cell lines 
6.3.1 TGF-β treatment induces EMT in NSCLC cell lines 
TGF-β is known to play a crucial role in tumorigenesis [209] and high TGF-β levels are 
correlated to poor prognosis in lung cancer [125, 127]. Therefore, the NSCLC cell lines 
H838, H1975 and H1650 were tested for their ability to signal via the TGF-β receptor. 
As markers for the activation of TGF-β signaling, the phosphorylation of SMAD2 and 
SMAD3 upon stimulation with TGF-β examined and it was shown that at the protein 
level TGF-β was able to start the TGF-β signaling cascade in all analyzed cell lines. 
However, in the cell line H1975 high pSMAD2 levels additionally to pSMAD3 could be 
detected in contrast to H1650 and H838 that showed only weak phosphorylation of 
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SMAD3 upon TGF-β stimulation. Moreover, the TGF-β target gene SMAD7 [99, 163] 
that is known to serve as negative feedback regulator of the SMAD complexes and 
TGFBR1 [111] was rapidly expressed upon TGF-β stimulation in H1975 cells and 
remained sustained over the 48 hours observed. 
Further insights into the impact of TGF-β signaling on mRNA expression were obtained 
by categorizing the TGF-β-induced target genes in H1975 cells using the gene ontology 
database. The identified biological processes were clustered into “up- or downregulated 
by TGF-β”.  Among the downregulated biological processes, mitosis, cell division, cell 
cycle and DNA repair as well as replication were detected. In contrast, TGF-β 
upregulated processes were connected to cell adhesion, cell junctions, cell migration 
and epithelial-to-mesenchymal transition (EMT).  
The TGF-β-induced expression of some mRNAs was verified by qRT-PCR in H1975 
and additionally in H838 cells . TGF-β mediated up-regulation of the mRNA expression 
was verified for SNAI1 (Snail protein), SMURF1, JUNB, KLF10, MAP3K4 and CDKN1A 
(p21 protein) in H1975 cells. In the cell line H838, MAP3K9 and XIAP mRNAs were not 
significantly changed and all tested mRNAs showed weaker inducibility upon TGF-β 
treatment in comparison to H1975 cells. These findings suggest that in general the 
TGF-β pathway can be activated to a higher extend in H1975 compared to H838 cells 
correlating with higher pSMAD2 and pSMAD3 levels in H1975 cells compared to H838 
cells. 
Previous microarray analysis showed that the adenocarcinoma cell line A549 compared 
to the lung epithelial cell line HPL1D expressed upon TGF-β stimulation not only 
expressed regulators of the cytoskeleton and cell-cell junctions, but also genes involved 
in the MAPK pathways [210]. A mRNA microarray analysis of in lung fibroblasts showed 
that TGF-β induces several genes involved in matrix formation, cytoskeletal remodeling, 
cell adhesion and metabolism [211]. 
The key process that was found to be up-regulated upon stimulation with TGF-β in the 
NSCLC cell line H1975 was EMT. This was not surprising as it is known that TGF-β 
induces EMT in many cell types including mammary epithelial cells and cancer, 
including lung cancer [118-122]. Moreover, the results of the mRNA expression analysis 
are in line with observed loss of the epithelial character during EMT (Reference)  that is 
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known to be connected to cell cycle arrest and disassemble of cell junctions and 
adhesion. For instance, it was reported that stimulation with TGF-β results in cell cycle 
attenuation via the expression of the EMT marker Snail in embryogenesis [212] which is 
known to induce p21 expression and thereby arrests the cell cycle in human mammary 
cells [213] and in pancreatic cancer cell lines [214]. Snail, that was also found to be 
upregulated in the qRT-PCR studies in H1975 cells, is further known to be a key 
regulator of the disassemble of cell junctions in human embryonic kidney cells, mouse 
keratinocytes [215] and mouse embryogenesis [216]. SMURF1, that was also monitored 
by qRT-PCR to be upregulate in H1975 cells upon TGF-β treatment, was shown to 
negatively regulate SMAD proteins, but also to be essential for the loss of tight junctions 
in mammary gland epithelial cells [217]. The loss of epithelial cell junctions was shown 
to lead to acquired motility and invasive properties [209, 218]. Moreover, MAP kinases 
were also shown to be significantly induced by TGF-β in H1975 cells. This is in 
agreement with reports that TGF-β was able to induce MAPK pathways in epithelial 
cells [219] and in the lung adenocarcinoma cell line A549 [210]. The importance of the 
MAP kinases for TGF-β-induced EMT was shown by the inhibition of MEK, which 
resulted in the loss of the ability to disassemble adherent junctions in murine mammary 
and epithelial cells [220] and in pancreatic cancer cell lines [221]. MAP3K4 was even 
shown to correlate with TGF-β-mediated phosphorylation of the p38 MAPK in mouse 
embryonic fibroblasts and keratinocytes [222]. 
In conclusion, TGF-β treatment resulted in the downregulation of genes involved in 
mitosis, cell division, cell cycle and DNA repair and replication and upregulation of 
genes that are connected to cell adhesion, cell junctions and migration. All these 
processes can be connected to EMT, which was also among the detected upregulated 
processes.  
 
6.3.2 Role of BAMBI as a potential tumor suppressor 
This study showed that TGF-β induced the development of mesenchymal properties by 
EMT in the NSCLC cell line H1975. As it was shown that the BAMBI protein, a negative 
regulator of the TGF-β signaling pathway, is absent in lung adenocarcinoma tissue 
Discussion  82 
 
 
 
sample of patients, the expression level of BAMBI and its influence on NSCLC cells was 
tested. 
BAMBI mRNA was shown by qRT-PCR to be downregulated in lung adenocarcinoma 
tumors of matched pairs of tumor and tumor-free lung of tissues from 9 patient. In 
agreement with these results, BAMBI was significantly lower expressed in the NSCLC 
cell lines H838, H1650 and H1975 compared to the control healthy lung epithelial cells 
type II. Interestingly, BAMBI was found to be epigenetically silenced in bladder cancer 
[115] and is absent in breast cancer [116]. Moreover, BAMBI was shown to be 
upregulated in the lung upon treatment with nontypeable haemophilus influenzae [223]. 
In contrast, BAMBI was reported to be over-expressed in ovarian cancer [114] and 
colorectal cancer tissues [224, 225].  
The measurements further revealed that the TGF-β receptors 1 and 2, as well as 
SMAD7 and the EMT markers SNAI1 (Snail), SNAI2 (Slug), ZEB1, VIM (Vimentin), FN1 
(Fibronectin) and CDH2 (N-cadherin) were downregulated in the tumors tested. It was 
shown for NSCLC that loss of TGFBR2 is associated with more aggressive tumor 
behavior [226] and is connected to high invasion rates and poor outcome in lung 
adenocarcinoma [129]. 
BAMBI was reconstituted in the NSCLC cell line H1975 with the intention to reestablish 
the healthy status in the cancer cell. A TGF-β-treated mRNA time course, including the 
measurement of SMAD7, TGFBR1 and TGFBR2, ZEB1, SNAI1, SNAI2, FN1, CDH1, 
CDH2, VIM and SKIL revealed the effect of different BAMBI expression levels. The 
tested genes showed similar signaling dynamics but in a reduced manner with BAMBI 
reconstitution compared to the wild type H1975 cells. However, the EMT markers 
analyzed were shown to be upregulated upon TGF-β treatment, which confirms the 
mRNA expression analysis by microarray where EMT was shown to be the key process 
upregulated by TGF-β. 
It was hypothesized that low BAMBI levels sensitize NSCLC cells to TGF-β. In 
conclusion, the treatment with TGF-β results in increased activation of the EMT markers 
that is connected to increased EMT and thus tumorigenesis. As ZEB1, Snail, Slug, 
Vimentin, E-cadherin and N-cadherin are EMT key regulators, it can be concluded that 
the BAMBI expression is negatively correlated to the potential for EMT and thus 
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metastasis in NSCLC. BAMBI is thereby suggested to act as a tumor suppressor in 
NSCLC.  
 
6.4 Conclusions and outlook 
In this study, the impact of growth factors, therapeutic inhibitors and cytostatic 
compounds on the response of non-small-cell lung carcinoma cell lines was analyzed 
(Figure 30). In detail, the transforming growth factor beta (TGF-β) was shown to induce 
EMT in NSCLC cells that is connected to the attenuation of the cell cycle, the 
disassemble of cell-cell contacts and increased metastatic properties. The standard of 
care for metastasizing NSCLC tumors is the chemotherapeutic agent cisplatin that was 
shown to induce apoptosis via the cleavage of caspase-3 predominantly in dividing 
NSCLC cells. The cisplatin-induced induction of the RAS–RAF–MEK–ERK cascade 
could be blocked with MEK inhibitors that are currently tested in clinical trials to 
determine their potential for the inhibition of constitutive activated MAP kinase signaling 
that might lead to uncontrolled cell proliferation or resistance to chemotherapeutic 
agents. Unfortunately, MEKi treatment was shown to decrease the sensitivity of NSCLC 
cells to cisplatin. As mechanism, an indirect rescue effect by arresting the cells in the 
G1 cell cycle phase was suggested. Furthermore, the presence of EpoR in the NSCLC 
cell line H838 resulted in response to Epo stimulation in a rescue effect of cisplatin-
induced apoptosis that is believed to be mediated by phosphorylated STAT5. 
However, a verification of these findings in primary tumor cells or in vivo mouse models, 
as well as with patient samples might be required, as almost all experiments were 
performed with NSCLC cell lines. 
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Figure 30: Impact of growth factors, therapeutic inhibitors and cytostatic compounds on the 
response of non-small-cell lung carcinoma cells. The origin of NSCLC cells is believed to be lung 
alveolar epithelial cells type II (AECII). NSCLC cells undergo EMT upon TGF-β treatment, which is 
connected to repression of the cell cycle, the disassemble of cell-cell contacts and increased metastatic 
properties. Treatment with the chemotherapeutic agent cisplatin induces apoptosis predominantly in 
dividing cells. The sensitivity for cisplatin can be decreased in NSCLC cells by the treatment with MEK 
inhibitors (MEKi) or upon Epo treatment. 
 
In conclusion, the complexity of signaling pathways upon different or even combined 
treatments is quite high and may result in unintended effects. For instance, MEKi 
treatment in combination with cisplatin-based chemotherapy was shown to pose a 
potential risk for lung cancer patients. Furthermore, genetic alteration, such as the 
presence of EpoR in NSCLC cell lines results in response to Epo stimulation in a 
decreased sensitivity to cisplatin. To unravel complex signaling properties and to 
identify regulatory network, a systems biology approach might be required.  
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7. Materials and methods 
7.1 Software and general equipment  
Canvas 15 (for graphics) 
CellDesigner 4.4 (for graphical representation of ODE model) 
LightCycler 480 (for qRT-PCR, Roche Diagnostics) 
Imaris (for image processing of confocal stacks) 
ImageJ (for amage analysis, http://imagej.net/) 
SigmaPlot (for graphs, significance test) 
I control (for fluorescence measurements at the infinite F200 pro Reader, TECAN) 
Image Quant LAS 4000 (for the quantification of immunoblots, GE Healthcare) 
 
7.2 Cell culture chemicals, solutions and media for NSCLC cell lines 
Substance Additional information Cat. No (company) 
DMEM without phenol red, without glutamine BE12-917F (Lonza) 
DMEM with phenol red BE12-604F (Lonza) 
HEPES BUFFER 1M   15630056 (Invitrogen) 
Pen/Strep 100x 10,000 μg/ml Strep., 10,000 U/ml Pen. Cat# 15070063 (Invitrogen) 
L-Glutamin 200mM   Cat# 25030024 (Invitrogen) 
BSA   A9418 (Sigma) 
PBS (DPBS) -Mg2+, -Ca2+ PO4-36500l (PAN Biotech) 
Trypsin/EDTA 0.05% Trypsin, 4Na EDTA 25300054 (Invitrogen) 
Puromycin   P7255 (Sigma) 
Doxycyclin   D9891 (Sigma) 
Staurosporine   380-014-M001 (Enzo) 
G418 (Neomycin)   A1720 (Sigma) 
EDTA   E5134 (Sigma) 
Glycerol   15523 (Sigma) 
Old FCS Australian origin 10099141 (Invitrogen) 
New FCS South American origin 10270098 (Invitrogen) 
Table 3: List of chemicals, solutions and media 
 
Three different media types were used depending on the application (Table 4). For 
selection purposes, puromycin and/or neomycin was additionally added. For instance, 
H838-GFP and H838-EpoR cells were cultured with 1 µg/ml puromycin and H838-
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EpoR-CasperGR cells received 1 µg/ml puromycin and 400 µg/ml neomycin. The 
expression of either BAMBI-GFP or GFP from either H1975-TRET-BAMBI-GFP or 
H1975-TRET-GFP cells was induced by addition of 5 µl/ml doxycylin. 
 
Medium type DMEM Cat. No. (company) Supplemented with: 
Amplification medium BE12-604F (Lonza) 10 % FCS, 100 µg/ml Penicillin, 100 U/ml Streptomycin 
Medium to seed cells for 
experiments BE12-917F (Lonza) 
10 % FCS, 100 µg/ml Penicillin, 100 U/ml 
Streptomycin, 2mM L-Glutamin 
Growth factor depletion 
medium BE12-917F (Lonza) 
100 µg/ml Penicillin, 100 U/ml Streptomycin, 
2mM L-Glutamin, 1 mg/ml BSA 
Table 4: List of different medium types, its composition and application. 
 
7.3 Cell culture plastic ware and volumes for the amplification and experiments 
with NSCLC cell lines 
  diameter of plate multi well plates 
  15 cm 10 cm 6 cm 6 well 12 well 24 well 96 well(flat) 
company TPP TPP TPP TPP TPP TPP TPP 
plastic type PS PS PS PS PS PS PS 
coating yes yes yes yes yes yes yes 
product number 93150 93110 93060 92006 92012 92024 92096 
growth surface [cm²] 147.8 60.1 22.1 8.96 3.6 1.86 0.34 
internal diam. [mm]  137 87 53 33.78 21.4 15.4 6.54 
volume [ml] 25 10 3.5 1.5 0.6 0.3 0.06 
ml/cm2 growth area 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
Table 5: List of the plastic ware including dimensions and appropriate volumes. 
 
7.4 Inhibitors 
For experiments that include inhibitor treatments, cells were pre-incubated with the 
according inhibitor for 60 minutes. All inhibitors were diluted in DMSO with a stock 
concentration of 10 mM. 5 µM LY294002 and Akt Inhibitor VIII were applied for the 
treatment of the NSCLC cell lines. The standard working concentrations for the 
inhibitors U0126 and selumetinib were 2.5 or 10 µM, for Cl-10-40 1 and 5 µM and for  
PD0325901 and trametinib 0.001 and 0.1 µM. 
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Inhibitor Additional information Cat. No (company) 
LY294002 PI3 Kinase Inhibitor 9901 (Cell Signaling) 
Akt Inhibitor VIII Akt-1/2/3 Inhibitor 124017 (Millipore) 
U0126 MEK1/2 Inhibitor 9903 (Cell Signaling) 
Selumetinib (AZD6244) MEK1 Inhibitor 2234-5 (BioVision) 
Cl-1040 (PD184352)  MEK1/2 Inhibitor 1585 (BioVision) 
PD0325901 MEK1/2 Inhibitor SPD131 (System Biosciences) 
Trametinib (GSK1120212) MEK1/2 Inhibitor sc-364639 (Santa Cruz) 
U0126 MEK1/2 Inhibitor 9903 (Cell Signaling) 
Table 6: List of inhibitors. 
 
7.5 Treatments 
The standard working concentrations for cisplatin were 5 or 10 mg/ml. 5 U/ml Epo-α 
was applied for mouse experiments and 10 or 500 U/ml Epo-β was used for the 
treatment of human NSCLC cell lines. 1 or 10 mg/ml TGF-β was applied on NSCLC cell 
lines. 40 ng/ml HGF was applied on NSCLC cell lines. 1 µg/ml actinomycin D was used 
to block RNA synthesis. 
 
Treatment Additional information Cat. No (company) 
Cisplatin chemotherapeutic drug CisTeva (Ratiopharm) 
Epo-α applied on mCFU-Es ERYPO FS 10 000  I.E./ml (Janssen-Cilag) 
Epo-β (EPOsf) applied on NSCLC cell lines 36016762 (Roche) 
TGF-β applied on NSCLC cell lines 240B (R&D systems) 
HGF applied on NSCLC cell lines 294HG (R&D systems) 
Actinomycin D applied on NSCLC cell lines A1410 (Sigma) 
Table 7: List of treatments. 
 
7.6 Antibodies 
For the detection of cleaved caspase-3 and pERK1/2, the primary antibodies were 
diluted 1:1000. For EpoR, ERK1/2, pEpoR and β-actin detection, a 1:10,000 dilution 
was used. Either horseradish peroxidase conjugated goat anti-rabbit (Dianova, 111-
035-144), goat anti-mouse (Dianova, 115-035-146) or protein A HRP (Amersham 
Biosciences) were applied as secondary antibodies in 1:10,000 dilution. 
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Prot. detected Antibody Mol. weight Company Article # Source 
Cl. caspase-3  18 Cell signaling 9664 rabbit 
EpoR C20 65 Santa Cruz sc-695 rabbit 
ERK1/2 p42/44 44, 42 Cell signaling 9102 rabbit 
pEpoR pTyr 80 Upstate (millipore) 16-101 Mouse (protein A HRP) 
pERK1/2 pp42/44 44, 42 Cell signaling 9101 rabbit 
ß-actin  42-45 Sigma A5441-.2ML mouse 
Table 8: List of immunoblot antibodies. 
 
7.7 Cell culture SOPs and cell-based techniques 
7.7.1 NSCLC cell lines 
The NSCLC cell lines H838, H1975 and H1650, were purchased from ATCC and 
cultivated in DMEM amplification medium (Table 4, Table 5). Cells were always 
incubated at 37°C with CO2.  
 
Cell line ATCC no Smoker Age Stage Gender Tissue 
H1975 CRL-5908 no   female lung 
H838 CRL-5844 yes 59 3b male lung; metastatic site (lymph node) 
H1650 CRL-5883 yes 27 3b male lung; derived from metastatic site 
Table 9: NSCLC cell lines selected for the main experiments. 
 
The cell lines H838-GFP, H838-EpoR, H838-EpoR-CasperGR, H1975-TRET-GFP and 
H1975-TRET-BAMBI-GFP were kindly provided by Dr. Sofia Depner. 
 
7.7.2 Detaching and amplification of NSCLC cells 
Medium was aspirated and EDTA/PBS was added according to medium volumes 
(Table 4, Table 5) and incubated for 5 minutes at 37°C with CO2. EDTA/PBS was 
replaced by 0.025% Trypsin/EDTA/PBS (0.05% Trypsin/EDTA stock diluted with PBS 
1:2) and incubated for 5 minutes at room temperature. Cells were washed down in 
Trypsin/EDTA/PBS before medium was added to stop the trypsinization. After 
centrifugation (5 minutes, 1000 rpm, room temperature), the supernatant was discarded 
and the cells were resuspended in pre-warmed medium and counted using a Neubauer 
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counting chamber. For amplification, cells were splitted 1:4 (for 3 days) or 1:5 (for 4 
days) and plated in amplification medium (Table 4, Table 5). 
 
7.7.3 Freezing and thawing of NSCLC cells 
Cells were detached (see Detaching and amplification of NSCLC cells) and frozen at 
the concentration of 2.5*106 cells/ml. A Neubauer counting chamber was used to 
determine the cell number. The freezing medium contained 80% amplification medium 
(Table 5) with 10% FCS and 10% glycerol. The cells were aliquoted into a cryo tube 
and incubated for one day at -80°C in freezing containers containing isopropanol. Cells 
were stored in liquid nitrogen. 
For the amplification, freshly thawed cells were mixed with 9 ml pre-warmed medium 
and seeded on appropriate 10cm-plastic plates (Table 4, Table 5). Medium was 
exchanged on the next day to remove residual glycerol. 
 
7.7.4 Seeding NSCLC cells for experiments 
NSCLC cells were seeded in medium to seed cells for experiments (Table 4, Table 5) 
three days before the experiment to have them about 80% confluent at the day of the 
experiment (Table 10, Table 11). Before each experiment and prior to any treatment or 
stimulation (Table 7, Table 7), growth factor depletion over night was applied without 
phenol red. Cells were always incubated at 37°C with CO2. A Neubauer counting 
chamber was used to determine the cell number. 
 
  seed cells/cm2 after 3d cells/cm2 
15 cm plate 2.00E+06 1.35E+04 7.39E+06 5.00E+04 
10 cm plate 8.11E+05 1.35E+04 3.01E+06 5.00E+04 
6 cm plate 2.98E+05 1.35E+04 1.11E+06 5.00E+04 
6 well-plate 1.20E+05 1.35E+04 4.46E+05 5.00E+04 
12 well-plate 4.86E+04 1.35E+04 1.80E+05 5.00E+04 
24 well-plate 2.51E+04 1.35E+04 9.30E+04 5.00E+04 
96 well-plate 4.52E+03 1.35E+04 1.68E+04 5.00E+04 
Table 10: SOPs for  the seeding of the H838 cells. 
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  seed cells/cm2 after 3d cells/cm2 
15 cm plate 2.21E+06 1.50E+04 5.17E+06 3.50E+04 
10 cm plate 9.00E+05 1.50E+04 2.10E+06 3.50E+04 
6 cm plate 3.31E+05 1.50E+04 7.74E+05 3.50E+04 
6 well-plate 1.33E+05 1.50E+04 3.12E+05 3.50E+04 
12 well-plate 5.39E+04 1.50E+04 1.26E+05 3.50E+04 
24 well-plate 2.79E+04 1.50E+04 6.51E+04 3.50E+04 
96 well-plate 5.02E+03 1.50E+04 1.17E+04 3.50E+04 
Table 11: SOPs for  the seeding of the H1975 cells. 
 
7.7.5 AECII cells 
Freshly isolated human alveolar epithelial type II cells (AECII) were kindly provided by 
Prof. Heimo Mairbäurl (University of Heidelberg, Sports medicine). The cells were 
cultivated in low glucose medium (provided by the group of Prof. Heimo Mairbäurl, 
DMEM Low Glucose from Sigma-Aldrich Cat.No. D5546, supplemented with 10 % FCS) 
for two days. Afterwards, low glucose medium was replaced by DMEM medium for 
experiments (Table 5 and Table 5). 
 
7.7.6 Tumor samples adenocarcinoma 
The cDNA of matched pairs of tumor and tumor-free lung of 9 patients were kindly 
provided by the cooperation partner Dr. Sebastian Marwitz in the group of Prof. Torsten 
Goldmann (Research Center Borstel, Division of Clinical and Experimental Pathology). 
 
7.7.7 Preparation of murine fetal liver cells (CFU-Es) 
At E13.5 Balb/c mouse embryos were dissected from the uterus of killed females. Fetal 
livers were resuspended in PBS/0.3% BSA and passed through a 40‐μm cell strainer 
(BD Biosciences). Fetal liver cells were treated with 9 ml Red Blood Cell Lysis Buffer 
(Sigma‐Aldrich) to remove erythrocytes. For sorting TER119− erythroid progenitors, 
FLCs were incubated with rat antibodies against the following surface markers: GR1, 
CD41, CD11b, CD14, CD45R/B220, CD4, CD8 and Ter119 (BD Pharmingen), and 
42.2.2 for 30 min at 4°C. After washing, cells were incubated for 30 min at 4°C with anti‐
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rat antibody‐coupled magnetic beads and negatively sorted with MACS columns 
according to the manufacturer's instructions (Miltenyi Biotech). Sorted CFU‐E cells were 
cultivated for 12–14 h in Panserin401 (PAN-biotech) supplemented with 50 µM ß-
mercaptoethanol and 0.5 U/ml Epo-α. For experiments, the CFU-Es were seeded at a 
cell density of 4x106 cells/ml in Panserin401. Before the experiments, the CFU-Es were 
growth-factor-starved for 60 minutes. 
 
7.7.8 CellTiter-Blue cell viability assay 
The cells for the experiment were seeded according to the SOPs (7.7.4 Seeding 
NSCLC cells for experiments, Table 4, Table 5). For the determination of the EC50 in 
the cell line H838, a dilution series of 100, 50, 25, 12.5, 6.25, 3.125, 1.562, 0.7813 mg/l 
cisplatin (Table 7) was applied. Apoptosis was induced in further experiments by 
applying 5 or 10 mg/l cisplatin.  In combination with 10 U/ml Epo, 5 mg/l cisplatin was 
used. The determination of the sensitivity of MEK inhibitors was performed with 5 and 
10 mg/l cisplatin and 2.5 or 10 µM U0126 and selumetinib, 1 and 5 µM Cl-10-40 and 
0.001 and 0.1 µM PD0325901 and trametinib (Table 6). 
To measure the viability of cells, CellTiter-Blue Viability Assay (Promega, #G8081) was 
applied according to the manufacturer’s instructions. Incubation with the dye for 60 min 
was followed by measurement of the fluorescence with the infinite F200 pro Reader 
(TECAN). A blank well without cells was measured to determine the background. After 
subtraction of the background, cell dilution series enabled due to a direct correlation of 
the signal intensities with the cell number, the verification of absolute cell numbers. 
 
7.8 Molecular biology: RNA 
7.8.1 RNA extraction 
The cells for the experiment were seeded according to the SOPs (7.7.4 Seeding 
NSCLC cells for experiments, Table 4, Table 5). Treatments were applied as 
described (Table 6 and Table 7). For the determination of the effect of MEK inhibition 
on cisplatin-induced apoptosis on RNA level, 2.5 µM U0126 was applied in combination 
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with 10 mg/l cisplatin. The standard working concentration for all experiments including 
Epo was 10 U/ml Epo-β for human cells and 5 U/ml Epo-α for mouse cells. For the 
TGF-β-treated time course analyzed by qRT-PCR, the standard working concentration 
was 1 ng/ml TGF-β and the time course analyzed by microarray, was stimulated with 10 
ng/ml TGF-β (Table 6, Table 7). 
To extract total RNA, including small RNAs like miRNAs, miRNeasy Mini Kit (QIAGEN) 
was employed according to the manufacturer’s instructions. If just the mRNA was 
needed, RNA was extracted using the RNeasy Mini Plus Kit (QIAGEN) according to the 
manufacturer's instructions.  
 
7.8.2 Quantitative Real Time PCR (qRT-PCR) 
The concentration and sample purity of total RNA samples were determined by 
measuring the absorbance at 260 and 280nm (A260/280) by NanoDrop (Thermo 
scientific). For quantitative RT-PCR, complementary DNA was generated with the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and analyzed using the 
LightCycler 480 with the Universal ProbeLibrary (UPL) platform (Roche Applied 
Science).  
In general, qRT-PCR amplifications were performed in 384-well format in an 11 µl 
reaction volume containing 5 µl of diluted template cDNA, 0.2 µM of forward and 
reverse primer, 0.2 µl of the appropriate UPL probe and 6 µl LightCycler 480 Probes 
(Table 12, Table 13). Master solution (Roche Diagnostics, Mannheim) according to the 
manufacturer’s manual. Primer pairs were generated using the automated UPL Assay 
Design Center (www.roche-applied-science.com). 
Crossing point values were calculated using the second derivative maximum method of 
the LightCycler 480 Basic Software (Roche Diagnostics, Mannheim). PCR efficiency 
correction was performed for each PCR setup individually based on a dilution series of 
template cDNA. For the relative correlation between different cell types, the efficiency 
was assumed to be 100%. 
The values were normalized for the NSCLC cell lines individually if not compared 
amongst each other by using the geometric mean of ESD and GUSB mRNA levels. 
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If not other stated, primers target all transcript variants of the according gene. 
 
Gene Protein Primer forward/reverse UPL Probe 
BAMBI BAMBI cgccactccagctacatctt/cacagtagcatcgaatttca 71 
BCL2 Bcl-2 tacctgaaccggcacctg/gccgtacagttccacaaagg 75 
CCNA1 CyclinA1 tcagtaccttagggaagctgaaa/ccagtccaccagaatcgtg 71 
CCNB1 CyclinB1 acatggtgcactttcctcct/aggtaatgttgtagagttggtgtcc 18 
CCND1 Cyclin D1 gctgtgcatctacaccgaca/ttgagcttgttcaccaggag 17 
CCNE1 CyclinE1 ggccaaaatcgacaggac/gggtctgcacagactgcat 36 
CDH1 E-Cadherin tggaggaattcttgctttgc/cgctctcctccgaagaaac 84 
CDH2 N-Cadherin ggtggaggagaagaagaccag/ggcatcaggctccacagt 66 
CDKN1A p21 tcactgtcttgtacccttgtgc/ggcgtttggagtggtagaaa 32 
CDKN1B p27 tcactgtcttgtacccttgtgc/ggcgtttggagtggtagaaa 32 
FOS cFos actaccactcacccgcagac/ccaggtccgtgcagaagt 67 
CISH Cis agccaagaccttctcctacctt/tggcatcttctgcaggtgt 20 
DUSP5 DUSP5 caaatggatccctgtggaa/cccttttccctgacacagtc 5 
DUSP7 DUSP7 cccatctctgaccactggag/caggacaccacacttcttgg 14 
DUSP8 DUSP8 gaccattgcggagctcat/tcatagaccaccacgtcctgt 39 
EGR1 Egr1 agccctacgagcacctgac/ggtttggctggggtaactg 22 
EGR3 Egr3 ttggaggacttggtgtgtttc/agcttccatggctcatcct 74 
ELK1 Elk1 tgcttcctacgcatacattga/ggtgctccagaagtgaatgc 16 
EpoR Epo receptor caatctgtaccccgaggaga/cagaccgatgtccattacattc 69 
ESD ESD ttagatggacagttactccctgataa/ggttgcaatgaagtagtagctatgat 27 
FN1 Fibronectin ctggccgaaaatacattgtaaa/ccacagtcgggtcaggag 32 
GUSB GUSB cgccctgcctatctgtattc/tccccacagggagtgtgtag 57 
JUNB JunB atacacagctacgggatacgg/gctcggtttcaggagtttgt 49 
KLF10 KLF10 tctgaaggcccacacgag/acctcctttcacaacctttcc 2 
LTBP1 LTBP1 tgctacgagggctacaggtt/gcagaggtgttggacctga 6 
LTBP2 LTBP2 agggctccttcaactgtctatg/ccatagtcctcacactcgtcaa 11 
MAP3K1 MAP3K1 caccaccactgcatgtcaa/gatctacaaaggggacatattaaagg 29 
MAP3K2 MAP3K2 tctggctcaggaagttgtcc/agctctgagccctaggcatt 58 
MAP3K4 MAP3K4 ggctttcagccccagttag/taacccaggaatttgcacct 79 
MAP3K9 MAP3K9 cagggttcaccagccttatg/catcctcttcaatgtcgatgg 71 
MAP4K4 MAP4K4 tggtcttgtggcattacagc/gctctcattggatgcatgtc 29 
MDM2 Mdm2 gactccaagcgcgaaaac/cagacatgttggtattgcacatt 68 
SKIL SnoN gaggctgaatatgcaggacag/cttgcctatcggcctcag 13 
SMAD7 SMAD7 acccgatggattttctcaaa/aggggccagataattcgttc 69 
SMURF1 SMURF1 ttccgaaggcccatacct/cagcttctcgtagagcttctca 31 
SMURF2 SMURF2 agaaattacatgagcagaacacattt/tgttgcgttgtcctctgttc 25 
Snai1 Snail gctgcaggactctaatccaga/atctccggaggtgggatg 11 
Snai2 Slug tggttgcttcaaggacacat/gttgcagtgagggcaagaa 7 
SOCS3 SOCS3 agacttcgattcgggacca/aacttgctgtgggtgacca 36 
SOX4 SOCX4 agccggaggaggagatgt/ttctcgggtcatttcctagc 20 
SPP1 SPP1 gagggcttggttgtcagc/caattctcatggtagtgagttttcc 18 
TGFBR1 TGF-β receptor 1 gcagacttaggactggcagtaag/agaacttcaggggccatgt 5 
TGFBR2 TGF-β receptor 2 caccgcacgttcagaagtc/tggatgggcagtcctattaca 43 
TP53 p53 aggccttggaactcaaggat/ccctttttggacttcaggtg 12 
VIM Vimentin tacaggaagctgctggaagg/accagagggagtgaatccag 13 
XIAP XIAP ttttgggacatggatatactcagtt/agcactttactttatcaccttcacc 68 
ZEB1 ZEB1 tttttcctgaggcacctgaa/aaaatgcatctggtgttccat 34 
Table 12: List of primers and probes used for qRT-PCR. 
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PCR step Temperature Time 
initial denaturation 95°C 5 min 
50 cycles 
melting 95°C 10 s 
primer annealing 60°C 30 s 
DNA synthesis and data acquisition 72°C 1 s 
cooling 40°C 2 min 
Table 13: PCR programm for qRT-PCR 
 
7.8.3 Gene expression arrays 
The mRNA microarray (GeneChip 2.0 ST, Affimetrix) was performed by the group of 
Prof. Gretz (Heidelberg University, Medical Faculty Mannheim) for the NSCLC cell lines 
H838, H1650 and H1975 (Table 9). The normalization and data analysis was done by 
Dr. Melanie Börries and Dr. Hauke Busch (Freiburg University). The miRNA microarray 
(Agilent) was performed by the Genomics & Proteomics Core Facility (DKFZ 
Heidelberg) and normalized and analyzed by Dr. Nikola Müller in the group of Prof. 
Fabian Theis (Helmholtz Zentrum München). 
 
7.8.4 RNA sequencing (RNAseq) 
The RNA sequencing (RNAseq) was performed by the Genomics & Proteomics Core 
Facility (DKFZ Heidelberg) for the NSCLC cell lines H838, H1650 and H1975 (Table 9). 
The analysis was done by Stephen Krämer and Dr. Naveed Ishaque in the group of 
Benedikt Brors (DKFZ Heidelberg). 
 
7.9 Molecular biology: DNA 
7.9.1 DNA extraction 
The NSCLC cell lines H838, H1650 and H1975 for the experiment were seeded 
according to the SOPs (7.7.4 Seeding NSCLC cells for experiments). The DNA 
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extraction was performed with the DNeasy Tissue Kit (QIAGEN) according to the 
manufacturer's instructions. 
 
7.9.2 WGS and MCIp 
The whole genome sequencing (WGS) and methyl-CpG immunoprecipitation (MCIp)-
based methylome sequencing was performed by the Genomics & Proteomics Core 
Facility (DKFZ Heidelberg) for the NSCLC cell lines H838, H1650 and H1975 (Table 9). 
The analysis was done by Stephen Krämer and Dr. Naveed Ishaque in the group of 
Benedikt Brors (DKFZ Heidelberg). 
 
7.10 Molecular biology: proteins 
7.10.1 Preparation of total cell lysates (TCL) 
The cells for the experiment were seeded according to the SOPs (7.7.4 Seeding 
NSCLC cells for experiments, Table 4, Table 5). The effect of MEK inhibition (Table 
6) on cisplatin-induced ERK phosphorylation and cleavage of caspase-3, was measured 
with 2.5 µM U0126 and 10 mg/l cisplatin (Table 6, Table 7). For the determination of the 
effect of MEK inhibition on HGF-induced phosphorylation levels of ERK1/2, 40 ng/ml 
HGF in combination with a dilution series of 0, 0.001, 0.01, 0.1, 1, 2.5, 5, 10, 20 µM 
U0126, selumetinib (AZD6244), Cl-1040 (PD184352), PD0325901 or trametinib 
(GSK1120212) were applied (Table 6). The detection of Epo receptor phosphorylation 
was performed with 10 U/ml Epo-β (Table 7). 
Detergent lysates of cells were prepared with 2x 1% NP40 buffer (1x buffer: 1% NP40, 
150 mM NaCl, 20 mM Tris pH 7.4, 10 mM NaF, 1 mM EDTA pH 8.0, 1 mM ZnCl2 pH 
4.0, 1 mM MgCl2, 1 mM Na3VO4, 10% Glycerol) supplemented with 2 µg/ml aprotinin 
and 200 µg/ml AEBSF. After 20 min of rotation at 4°C, the lysates were centrifuged for 
10 min at 20,000 g and 4°C. The supernatant was either used directly, processed 
further by immunoprecipitation or total cellular lysates were stored at -80°C. 
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7.10.2 Protein quantification 
To determine protein concentrations of cellular lysates the BCA Protein Assay Kit 
(Pierce) was used according to the manufacturer’s instructions. 
 
7.10.3 Immunoprecipitation of EpoR 
Immunoprecipitation was performed by adding 5 µl of the EpoR antibody MAB307 
(R&D) and 25 µl of Protein A sepharose (GE Healthcare) to the TCL and rotate over 
night at 4°C. The immunoprecipitates were washed twice with 1x 1% NP40 lysis buffer 
and once with TNE buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, pH 8.0, 100 
µM Na3VO4). Immunoprecipitates were immediately subjected to protein gel 
electrophoresis or stored at -80°C. 
 
7.10.4 SDS-PAGE 
Proteins were separated according to their electrophoretic mobility in a denaturing SDS-
PAGE. Protein samples were boiled for 3 min in SDS sample buffer. Protein samples 
were separated by 10% SDS-PAGE with low bis-acrylamide (GE Healthcare) and 
separated in a electric field in running buffer (192 mM glycine, 25 mM Tris, 0.1% SDS) 
(Table 14). The samples were centrifuged for 2 min at 15,700 g before loading. For total 
cell lysates, an amount of 50-100 µg protein resuspended in SDS sample buffer were 
separated by SDS-PAGE. 
 
  Stacking gel Separating gel 10% 
40% acrylamide 1 ml 5 ml 
2% w/v methylenebisacrylamide 0.5 ml 1.3 ml 
1M Tris-HCl, pH 6.8 1.25 ml - 
1.5M Tris-HCl, pH 8.8 - 5 ml 
10% SDS 0.1 ml 0.2 ml 
ddH2O 7.15 ml 8.5 ml 
APS (10 %) 100 µl 200 µl 
Temed 10 µl 20 µl 
Table 14: 10% polyacrylamide gels for SDS-Page. 
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7.10.5 Immunoblotting 
Immunoblotting was performed in semi-dry chambers (GE Healthcare) on nitrocellulose 
membranes with a pore size of 0.2 µm (Schleicher&Schuell) except of cleaved caspase-
3, which was detected on a nitrocellulose membrane with a pore size of 0.1 µm 
(Whatman).  
The blotting was performed in transfer buffer (192 mM glycine, 25 mM Tris, 0.075% 
SDS, 0.5 mM Na3VO4, 15% methanol) for 1 hour at approximately 1.3 mA/cm2. Proteins 
were reversibly stained with Ponceau Red. After blocking unspecific antibody binding 
with 5% BSA diluted in TBS-T (10 mM Tris pH 7.4, 150 mM NaCl, 0.2% Tween-20), 
membranes were incubated with the appropriate first and secondary antibodies (Table 
8) and proteins were visualized with the ECL or ECL Prime/select Western Blotting 
Detection Reagents (GE Healthcare) and subsequently detected on Image Quant LAS 
4000 (GE Healthcare). The quantification was performed using the specific software 
(GE Healthcare). To evaluate total protein levels, membranes were incubated in 
stripping buffer (62.5 mM Tris pH 6.8, 2% SDS, 100 mM β-mercaptoethanol) for 20-25 
min at 65°C, blocked with 5 % BSA diluted in TBS-T, and reprobed with the appropriate 
first and secondary antibody. 
 
7.11 Microscopy 
7.11.1 Caspase-3 assay 
For the caspase-3 activity assay, H838 cells over-expressing EpoR and additionally 
expressing the FRET-based CasperGR sensor (H838-EpoR-CasperGR, kindly provided 
by Dr. Sofia Depner). The sensor consists of green (GFP) and red fluorescent proteins 
(RFP) connected by the linker containing the caspase-3 cleavage sequence DEVD 
which leads to FRET between these fluorescent proteins. Caspase-3 activation leads to 
the cleavage of the DEVD sequence resulting in FRET elimination which is detectable in 
the changing ratio of green to red. The cells were seeded in 8-well plates (Thermo 
scientific, #155411) at a density of 20,000 cells/well. 24 hours after the seeding, the 
cells were growth factor-depleted for 16 hours and afterwards treated with 5 mg/l 
cisplatin and/or treated with 10 or 500 U/ml Epo-β or left untreated (Table 7). The cells 
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were imaged on an environment-controlled microscope (Zeiss LSM 710). Images were 
acquired every 20 minutes for 64 hours. Analysis was performed using ImageJ 
software. 
 
7.11.2 Volume measurements with GFP and Hoechst staining 
For the cell volume measurements, H838 cells stably expressing GFP (H838-GFP, 
kindly provided by Dr. Sofia Depner) were seeded in 8-well plates (Thermo scientific, 
#155411) at a density of 10,000 cells/well. 24 hours after the seeding, the cells were 
growth factor-depleted for 16 hours. The cells were stained with 1 µg/ml Hoechst 
(H33342, Sigma) and imaged on an environment-controlled microscope (Zeiss LSM 
710). Images were acquired with an EC Plan-Neofluor 40x/1.30 oil objective lens 
applying the z-stack method. The total cell volume (GFP) and the volume of the nucleus 
(Hoechst) were calculated with the Imaris software (Bitplane). 
 
7.11.3 Cell cycle analysis with the FUCCI sensor 
For the measurement of the cell cycle, H838 cells expressing the FUCCI sensor (kindly 
provided by Dr. Sofia Depner) were seeded in 8-well plates (Thermo scientific, 
#155411) according to the SOPs. 24 hours after the seeding, the cells were growth 
factor-depleted for 16 hours before the time course with different treatments started. To 
test the effect of MEKi on cisplatin induced apoptosis, the cells were pre-incubated with 
2.5 µM U0126 for 60 minutes followed by the treatment with 5 mg/l cisplatin. The cells 
were imaged on an environment-controlled Nikon Ti eclipse microscope in cooperation 
with Dr. Erika Kuchen in the group of Prof. Thomas Höfer (DKFZ Heidelberg). The 
analysis was performed by Dr. Carsten Maus in the group of Prof. Thomas Höfer (DKFZ 
Heidelberg) 
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7.12 Dynamic pathway modeling 
The reactions listed below are adapted for H838 and H838-EpoR from Bachmann et al. 
[62].  
 
Abbrevations  100 
 
 
 
8. Abbrevations 
µ micro 
ActD actinomycin D 
AECII alveolar epithelial cells type II 
ALK anaplastic lymphoma kinase 
Bad Bcl-2-antagonist of cell death 
BAMBI BMP and activin membrane-bound inhibitor homolog 
Bax BCL2-associated X protein 
Bcl-2 B-cell lymphoma 2 
Bid BH3 interacting domain death agonist 
Bik BCL2-interacting killer 
BSA bovine serum albumin 
CCN cyclin 
CDH1 E-cadherin 
CDH2 N-cadherin 
CDK cyclin-dependent kinase 
CDKN cyclin-dependent kinase inhibitor 
CFU-E colony forming unit-erythroid 
Cis cisplatin 
CISH cytokine-inducible SH2-containing protein 
cm centi meter 
CTR1 copper transporter 1 
Ctrl control 
d day(s) 
DMEM Dulbecco’s modiﬁed Eagle's medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DOX doxycyclin 
DUSP dual specificity protein phosphatase 
EC50 half effective concentration 
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ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
EGR1 early growth response 1 
ELK1 ETS domain-containing protein 
EMT epithelial-to-mesenchymal transition  
Epo erythropoietin 
EpoR erythropoietin receptor 
ERK extracellular signal-regulated kinase  
ESA erythropoiesis stimulating agent 
ESD esterase D 
FCS fetal calf serum 
FDA U.S. Food and Drug Administration 
FN1 Fibronectin 
FRET fluorescence resonance energy transfer 
GFP green fluorescent protein 
GO gene ontology 
GUSB glucuronidase beta 
h hour(s) 
HGF hepatocyte growth factor  
IAP inhibitor of apoptosis proteins 
IP immunoprecipitation 
I-SMAD inhibitory SMADs 
ITGB4 integrin beta 4 
JAK2 Janus kinase 2 
JNK c-Jun N-terminal kinase 
KRAS Kirsten rat sarcoma 
l liter 
MAPK mitogen-activated protein kinase 
MCIp methyl-CpG immunoprecipitation 
Mcl1 myeloid cell leukemia 1 
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Mdm2 mouse double minute 2 homolog 
MEKi MEK inhibitor 
mg milli gramm 
min minute(s) 
miRNA micro RNA 
MMR mismatch repair 
mRNA messenger RNA 
NER nuclear excision repair 
NSCLC non-small-cell lung carcinoma 
ODE ordinary differential equations 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PI3K phosphoinositide 3-kinase  
PIAS protein inhibitors of activated STATs  
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase 
PLAU plasminogen activator, urokinase 
PS polystyrene 
PTEN phosphatase and tensin homolog 
PTP protein tyrosin phosphatase 
PUMA p53 upregulated modulator of apoptosis 
qRT-PCR quantitative real time PCR 
RAS rat sarcoma 
RFP red fluorescent protein 
RNA ribonucleic acid 
RNAseq RNA sequencing 
R-SMAD receptor-regulated SMADs 
SCLC small-cell lung carcinoma 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SH2 domain Src Homology 2 domain 
SHP-1 Src homology region 2 domain-containing phosphatase-1 
SMAD mothers against decapentaplegic homolog 
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SMURF SMAD ubiquitination regulatory factor-1 
SNAI1 Snail 
SNAI2 Slug 
SOCS3 suppressor of cytokine signaling 3 
SOP standard operating procedures  
STAT signal transducers and activators of transcription 
t time 
TCL total cell lysate 
TGFBR TGF-β receptor 
TGF-β transforming growth factor beta 
TKI tyrosine kinase inhibitor 
TP53 tumor protein p53 
VIM Vimentin 
WGS whole genome sequencing 
XIAP X-linked inhibitor of apoptosis protein 
ZEB zinc finger E-box-binding homeobox 
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